

CONSOLIDATED FINANCIAL REPORT,  
SUPPLEMENTARY INFORMATION, UNIFORM  
GUIDANCE REPORTS AND SCHEDULE

Mayo Clinic  
Years Ended December 31, 2023 and 2022

Ernst & Young LLP



# Mayo Clinic

## Consolidated Financial Report, Supplementary Information, Uniform Guidance Reports and Schedule

Years Ended December 31, 2023 and 2022

### Contents

Independent auditor's report.....	1
Consolidated financial statements	
Consolidated statements of financial position.....	4
Consolidated statements of activities.....	5
Consolidated statements of cash flows.....	6
Notes to consolidated financial statements.....	7
Supplementary Information	
Financial Responsibility Supplemental Schedule required by the U.S. Department of Education.....	
	46
Schedule of Expenditures of Federal Awards.....	47
Schedule of Expenditures of Florida State Financial Assistance.....	76
Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance.....	77
Uniform Guidance Reports and Schedule	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i> .....	
	79
Report of Independent Auditors on Compliance for Each Major Federal Program and State Financial Assistance Project and Report on Internal Control Over Compliance Required by the Uniform Guidance and Chapter 10.650, <i>Rules of the Auditor General of the State of Florida</i> .....	
	81
Schedule of Findings and Questioned Costs.....	86



Ernst & Young LLP  
Suite 500  
700 Nicollet Mall  
Minneapolis, MN 55402

Tel: +1 612 343 1000  
ey.com

## Report of Independent Auditors

Board of Trustees  
Mayo Clinic

### Report on the Audit of the Financial Statements

#### Opinion

We have audited the consolidated financial statements of Mayo Clinic (“the Clinic”), which comprise the consolidated statements of financial position as of December 31, 2023 and 2022, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”).

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Clinic at December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Clinic, and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Clinic's ability to continue as a going concern for one year after the date that the financial statements are issued.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Clinic's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Clinic's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.



## Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. We have not performed any procedures with respect to the audited financial statements subsequent to February 16, 2024. The Financial Responsibility Supplemental Schedule required by the U.S. Department of Education and the Schedules of Expenditures of Federal Awards and Florida State Financial Assistance as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, respectively, are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from, and relates directly to, the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

## Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated February 16, 2024 on our consideration of the Clinic's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Clinic's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Clinic's internal control over financial reporting and compliance.

*Ernst + Young LLP*

February 16, 2024, except for the Schedules of Expenditures of Federal Awards and Florida State Financial Assistance, for which the date is June 25, 2024



**Consolidated Statements of Financial Position**  
**December 31, 2023 and 2022 (In Millions)**

	2023	2022
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 80	\$ 64
Accounts receivable for medical services	1,976	1,842
Other receivables	787	759
Other current assets	391	386
<b>Total current assets</b>	<b>3,234</b>	<b>3,051</b>
Investments	18,834	17,256
Other long-term assets	3,428	3,631
Property, plant, and equipment, net	6,431	5,887
<b>Total assets</b>	<b>\$ 31,927</b>	<b>\$ 29,825</b>
<b>Liabilities and net assets</b>		
Current liabilities:		
Accounts payable	\$ 847	\$ 752
Accrued payroll	873	849
Accrued employee benefits	181	176
Deferred revenue	65	64
Long-term variable-rate debt	620	620
Other current liabilities	491	470
<b>Total current liabilities</b>	<b>3,077</b>	<b>2,931</b>
Long-term debt, net of current portion	4,098	4,121
Accrued pension and postretirement benefits, net of current portion	813	819
Other long-term liabilities	2,303	2,083
<b>Total liabilities</b>	<b>10,291</b>	<b>9,954</b>
Net assets:		
Without donor restrictions	16,240	14,808
With donor restrictions	5,396	5,063
<b>Total net assets</b>	<b>21,636</b>	<b>19,871</b>
<b>Total liabilities and net assets</b>	<b>\$ 31,927</b>	<b>\$ 29,825</b>

See notes to consolidated financial statements.



**Consolidated Statements of Activities**  
**Years Ended December 31, 2023 and 2022 (In Millions)**

	2023			2022		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Revenue, gains, and other support:						
Medical service revenue	\$ 15,077	\$ —	\$ 15,077	\$ 13,781	\$ —	\$ 13,781
Grants and contracts	703	—	703	666	—	666
Investment return allocated to current activities	479	57	536	250	23	273
Contributions available for current activities	127	301	428	75	268	343
Other	1,200	—	1,200	1,227	—	1,227
Net assets released from restrictions	442	(442)	—	337	(337)	—
<b>Total revenue, gains, and other support</b>	<b>18,028</b>	<b>(84)</b>	<b>17,944</b>	<b>16,336</b>	<b>(46)</b>	<b>16,290</b>
Expenses:						
Salaries and benefits	9,667	—	9,667	9,170	—	9,170
Supplies and services	5,950	—	5,950	5,377	—	5,377
Depreciation and amortization	663	—	663	624	—	624
Facilities	388	—	388	350	—	350
Finance and investment	192	—	192	174	—	174
<b>Total expenses</b>	<b>16,860</b>	<b>—</b>	<b>16,860</b>	<b>15,695</b>	<b>—</b>	<b>15,695</b>
<b>Income (loss) from current activities</b>	<b>1,168</b>	<b>(84)</b>	<b>1,084</b>	<b>641</b>	<b>(46)</b>	<b>595</b>
Noncurrent and other items:						
Contributions not available for current activities, net	(17)	190	173	(22)	230	208
Unallocated investment return, net	788	227	1,015	(1,382)	(357)	(1,739)
Income tax expense	(41)	—	(41)	(23)	—	(23)
Benefit credit	344	—	344	175	—	175
Other	(162)	—	(162)	129	—	129
<b>Total noncurrent and other items</b>	<b>912</b>	<b>417</b>	<b>1,329</b>	<b>(1,123)</b>	<b>(127)</b>	<b>(1,250)</b>
<b>Increase (decrease) in net assets before other changes in net assets</b>	<b>2,080</b>	<b>333</b>	<b>2,413</b>	<b>(482)</b>	<b>(173)</b>	<b>(655)</b>
Pension and other postretirement benefit adjustments	(648)	—	(648)	2,859	—	2,859
<b>Increase (decrease) in net assets</b>	<b>1,432</b>	<b>333</b>	<b>1,765</b>	<b>2,377</b>	<b>(173)</b>	<b>2,204</b>
Net assets at beginning of year	14,808	5,063	19,871	12,431	5,236	17,667
Net assets at end of year	\$ 16,240	\$ 5,396	\$ 21,636	\$ 14,808	\$ 5,063	\$ 19,871

See notes to consolidated financial statements.



**Consolidated Statements of Cash Flows**  
**Years Ended December 31, 2023 and 2022 (In Millions)**

	2023	2022
Cash flows from operating activities:		
Cash from medical services	\$ 14,016	\$ 12,827
Cash from external lab services	927	938
Cash from grants and contracts	671	658
Cash from benefactors	373	345
Cash from other activities	1,051	1,140
Cash for salaries and benefits	(9,576)	(8,822)
Cash for supplies, services, and facilities	(6,212)	(5,798)
Interest and dividends received	303	196
Interest paid	(173)	(144)
Income taxes paid	(62)	(33)
<b>Net cash provided by operating activities</b>	<b>1,318</b>	<b>1,307</b>
Cash flows from investing activities:		
Purchase of property, plant, and equipment	(1,164)	(1,177)
Purchases of investments	(13,766)	(7,711)
Sales and maturities from investments	13,467	6,838
Investment in unconsolidated entities	(9)	(10)
<b>Net cash used in investing activities</b>	<b>(1,472)</b>	<b>(2,060)</b>
Cash flows from financing activities:		
Restricted gifts, bequests, and other	213	208
Borrowing on long-term debt	—	807
Payment of long-term debt	(36)	(237)
Payment on leases	(7)	(7)
<b>Net cash provided by financing activities</b>	<b>170</b>	<b>771</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>16</b>	<b>18</b>
Cash and cash equivalents at beginning of year	64	46
Cash and cash equivalents at end of year	<b>\$ 80</b>	<b>\$ 64</b>

See notes to consolidated financial statements.



Notes to Consolidated Financial Statements (In Millions)

---

**Note 1. Organization and Summary of Significant Accounting Policies**

**Organization:** Mayo Clinic and its Arizona, Florida, Iowa, Minnesota, Wisconsin and international affiliates (the Clinic) provide comprehensive medical care and education in clinical medicine and medical sciences and conduct extensive programs in medical research. The Clinic also provides hospital and outpatient services, and at each major location, the clinical practice is closely integrated with advanced education and research programs. The Clinic and most of its subsidiaries have been determined to qualify as tax-exempt organizations under Section 501(c)(3) of the Internal Revenue Code (the Code) and as a public charity under Section 509(a)(2) of the Code.

**Basis of presentation:** Included in the Clinic's consolidated financial statements are all of its wholly owned or wholly controlled subsidiaries. All significant intercompany transactions have been eliminated in consolidation. In addition, these statements follow generally accepted accounting principles applicable to the not-for-profit industry as described in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) *Topic 958, Not-for Profit Entities*.

**Use of estimates:** The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

**New Accounting Standards:**

Effective January 1, 2023, the Clinic adopted Financial Accounting Standards Board Accounting Standard Update (ASU) No. 2016-13, Financial Instruments - *Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*. This ASU provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other documents to extend credit held by a reporting entity. The adoption of this ASU did not materially impact the consolidated financial statements.

**Cash and cash equivalents:** Cash and cash equivalents include currency on hand, demand deposits with banks or other financial institutions, and short-term investments with maturities of three months or less from the date of purchase, which are not managed by the Clinic's investment managers.

**Accounts receivable for medical services:** Accounts receivable for medical services are based upon the estimated amounts expected to be paid from patients and third-party payors.

**Inventories:** Inventories, consisting primarily of medical supplies and pharmaceuticals, are stated at the lower of cost or net realizable value.

**Investments:** Investments in equity and debt securities, including alternative investments, are recorded at fair value (Notes 4 and 6). Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Realized gains and losses are calculated based on the average cost method. Investment income or loss (including realized and unrealized gains and losses on investments, interest, and dividends) is included in the consolidated statements of activities.

Notes to Consolidated Financial Statements (In Millions)

---

**Note 1. Organization and Summary of Significant Accounting Policies (Continued)**

Alternative investments (principally limited partnership interests in absolute return, hedge, private equity, real estate and natural resources funds) represent the Clinic's ownership interest in the respective partnership, which is valued at fair value based on net asset value (NAV) obtained from fund manager statements and historically audited financial statements. The investments in alternative investments may individually expose the Clinic to securities lending, short sales, and trading in futures and forward contract options and other derivative products. The Clinic's risk is limited to the investment's carrying value.

It is the Clinic's intent to maintain a long-term investment portfolio to support research, education and other activities. Accordingly, the total investment return is reported in the consolidated statements of activities in two categories. The investment return allocated to current activities is determined by a formula, which involves allocating five percent of a three-year moving average of investments related to endowments, and the matching of financing costs for the assets required for operations. Management believes this return is approximately equal to the real return that the Clinic expects to earn on its investments over the long term. The unallocated investment return, included in noncurrent and other items in the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to current activities, net of investment costs.

**Property, plant, and equipment:** Property, plant, and equipment are carried at cost if purchased or at fair value on the date received through affiliation or donation, less accumulated depreciation. Plant and equipment are depreciated over their estimated useful lives, ranging from three to fifty years using the straight-line method. Depreciation expense includes amortization of assets recorded under capital leases.

Costs associated with the development and installation of internal-use software are accounted for in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Subtopic 350-40)* of the FASB ASC. Accordingly, internal-use software costs are expensed or capitalized and amortized according to the provisions of the accounting standard.

**Leases:** The Clinic determines if an arrangement is a lease at inception. Operating leases are included in other long-term assets, other current liabilities, and other long-term liabilities in the consolidated statements of financial position. Finance leases are included in property, plant, and equipment, other current liabilities, and other long-term liabilities in the consolidated statements of financial position.

Right-of-use (ROU) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, the Clinic uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The implicit rate is used when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain the Clinic will exercise the option.

The Clinic defines a short-term lease as any lease arrangement with a lease term of twelve months or less that does not include an option to purchase the underlying asset. Short-term lease payments are recognized as expense on a straight-line basis over the lease term and variable lease payments in the period in which the obligation is incurred.

The Clinic has lease arrangements with lease and non-lease components, which are generally accounted for separately, except the Clinic has elected the practical expedient to not separate non-lease components for real estate leases. Additionally, for certain equipment leases, the Clinic applies a portfolio approach to effectively account for the ROU assets and liabilities.

Notes to Consolidated Financial Statements (In Millions)

---

**Note 1. Organization and Summary of Significant Accounting Policies (Continued)**

**Deferred revenue:** Deferred revenue consists of payments received in advance for grant, subscription, and tuition revenue. Deferred revenues are subsequently recognized as revenue in accordance with the Clinic's revenue recognition policies.

**Deferred compensation:** The Clinic offers eligible employees a nonqualified, tax-deferred compensation retirement plan. Employees defer compensation into the plan on a pretax basis. The compensation deferred under this plan is credited with earnings and losses as determined by the rate of return on investments selected by the plan participants. Each participant is fully vested in all deferred compensation and those earnings credited to their individual accounts. The amounts deferred under this plan is an unsecured obligation of the Clinic. The balances are reflected in investments and other long-term liabilities in the consolidated statements of financial position. The related investment return is reported in unallocated investment return, net, with a corresponding gain/loss representing benefit expense/income reported in the other - noncurrent section of the consolidated statements of activities.

**Asset retirement obligations:** The Clinic accounts for the estimated cost of legal obligations associated with long-lived asset retirements in accordance with *Asset Retirement and Environmental Obligations (Topic 410)* of the FASB ASC. The asset retirement liability, recorded in other long-term liabilities, is accreted to the present value of the estimated future costs of these obligations at the end of each period.

**Net assets:** Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

*Net Assets Without Donor Restrictions* - Net assets available for use in general operations and not subject to donor restrictions. The governing board has designated, from net assets without donor restrictions, net assets for an operating reserve and board-designated endowment.

*Net Assets With Donor Restrictions* - Net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Gifts of long-lived assets and gifts of cash restricted for the acquisition on long-lived assets are recognized as revenue when received. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

**Medical service revenue:** Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care.

**Grants and contracts:** Reciprocal grants and contracts revenue is recognized when the expenses have been incurred for the purpose specified by the grantor or in accordance with the terms of the agreement. Contributed grants and contracts revenue is recorded as conditions are met or immediately if deemed an unconditional contribution. Grant and contract amounts due to the Clinic are included in other receivables.

**Charity and uncompensated care:** The Clinic provides health care services to patients who meet certain criteria under its Charity Care Policy without charge or at amounts less than established rates. Since the Clinic does not pursue collection of these amounts, they are not reported as revenue. The estimated cost of providing these services was \$58 and \$54 in 2023 and 2022, respectively, calculated by multiplying the ratio of cost to gross charges for the Clinic by the gross uncompensated charges associated with providing care to charity patients. In addition to the charges related to the direct patient care provided under the Clinic's Charity Care Policy, the Clinic has programs offered to benefit the broader community and other governmental reimbursement programs. The Clinic also participates in

Notes to Consolidated Financial Statements (In Millions)

---

**Note 1. Organization and Summary of Significant Accounting Policies (Continued)**

various state Medicaid programs for indigent patients. The estimated unreimbursed cost of providing services related to Medicaid programs totaled \$624 and \$613 in 2023 and 2022, respectively.

**Contributions:** The Clinic classifies contributions that are available for current activities as revenue, based on the lack of specific donor restriction or the presence of donor restrictions and the ability of the Clinic to meet those restrictions within the year. Contributions of a perpetual nature or not available for current activities are classified in noncurrent and other items in the consolidated statements of activities. Development expenses of \$59 (\$42 allocated to current and \$17 allocated to noncurrent) and \$54 (\$32 allocated to current and \$22 allocated to noncurrent) were incurred in 2023 and 2022, respectively. The current portion is recorded in expenses, and the noncurrent portion is netted against contributions not available for current activities in the consolidated statements of activities. Unconditional promises to give and contributions are reported at fair value at the time of the gift. An allowance for uncollectible pledges receivable is estimated, based on a combination of historical experience and specific identification. Conditional promises to give are recognized at fair value when the barriers to entitlement are overcome or the possibility that a condition will not be met is remote.

The Clinic periodically receives works of art from various benefactors. These items are unique in nature and are held on display for the benefit and enjoyment of the Clinic's patients. It is the Clinic's policy to neither capitalize contributed works of art nor record the related contribution revenue.

**Income from current activities:** The Clinic's policy is to include in income from current activities all medical service and other revenue, grants and contracts, investment return allocated to current activities, contributions available for current activities, net assets released from restrictions, and substantially all expenses. Contributions not available for current activities, unallocated investment return, income tax expense, benefit credit, and those items not expected to recur on a regular basis are included in noncurrent and other items in the consolidated statements of activities.

**Noncontrolling interest in subsidiaries:** The Clinic attributed income of \$6 and \$33 for the years ended December 31, 2023 and 2022, respectively, to noncontrolling interests based on the ownership percentage of the noncontrolling interests in certain of the Clinic's consolidated subsidiaries. These amounts are recognized in net assets without donor restrictions on the consolidated statements of financial position. The balance in net assets without donor restrictions as of December 31, 2023 and 2022 was \$68.

**Subsequent events:** The Clinic evaluated events and transactions occurring subsequent to December 31, 2023 through February 16, 2024, the date of issuance of the consolidated financial statements. During this period, there were no subsequent events requiring recognition in the consolidated financial statements. Additionally, there were no unrecognized events requiring disclosure except as disclosed in Note 5.

## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

---

#### Note 2. Liquidity and Availability

Financial assets available for general expenditure within one year of the consolidated statement of financial position date are composed of the following at December 31:

	2023	2022
Cash and cash equivalents	\$ 80	\$ 64
Accounts receivable	1,976	1,842
Promises to give	325	319
Grants receivable	173	145
Other receivables	289	295
Investments	12,750	10,495
Total financial assets available within one year	<u>\$ 15,593</u>	<u>\$ 13,160</u>

As part of a liquidity management plan, the Clinic has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the Clinic has \$300 of available lines of credit for working capital (see Note 9 - Financing).

The Clinic's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. As described in Note 13 - Endowment, under the Clinic spending policy, \$303 from the endowments was available as of January 1, 2024 and \$280 from the endowments was available at January 1, 2023.

#### Note 3. Medical Service Revenue

Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Clinic bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Clinic. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Clinic believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Clinic's hospital receiving inpatient acute care services. The Clinic measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Clinic does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Clinic has elected to apply the optional exemption provided in *Revenue from Contracts with Customers (Topic 606-10-50-14(a))* and, therefore, is not required to disclose the aggregate amount of the

Notes to Consolidated Financial Statements (In Millions)

---

**Note 3. Medical Service Revenue (Continued)**

transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Clinic determines the transaction price based on standard charges for goods and services provided to patients, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Clinic's policy, and/or implicit price concessions based on historical collection experience.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

- **Medicare:** Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic, and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.
- **Medicaid:** Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.
- **Other:** Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Clinic's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Clinic. In addition, the contracts that the Clinic has with commercial payors also provide for retroactive audit and review of claims.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Clinic also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Clinic estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured, based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to medical service revenue in the period of the change. For the years ended December 31, 2023 and 2022, revenue recognized due to changes in its estimates of transaction price concessions for performance obligations satisfied in prior years was \$12 and \$14, respectively. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2023 and 2022, was not significant.

**Notes to Consolidated Financial Statements (In Millions)**

---

**Note 3. Medical Service Revenue (Continued)**

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the Clinic's historical settlement activity, including an assessment to ensure it is probable a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available) or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price for the years ended December 31, 2023 and 2022 were not significant. Receivables from third-party payors for final settlements was \$64 and \$60 for December 31, 2023 and 2022, respectively.

Patients who meet the Clinic's criteria for charity care are provided care without charge or at amounts less than established rates. Such amounts which are determined to qualify as charity care are not reported as revenue.

## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

#### Note 3. Medical Service Revenue (Continued)

The composition of medical service revenue based on the regions of the country in which the Clinic operates, its lines of business, and timing of revenue recognition for the years ended December 31, 2023 and 2022, are as follows:

	Year Ended December 31, 2023			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 5,583	\$ 1,271	\$ 1,566	\$ 8,420
Clinic	3,645	957	1,020	5,622
Senior Care and Nursing Home	15	—	—	15
Other	94	2	—	96
Total patient care service revenue	9,337	2,230	2,586	14,153
External lab	924	—	—	924
Total medical service revenue	<u>\$ 10,261</u>	<u>\$ 2,230</u>	<u>\$ 2,586</u>	<u>\$ 15,077</u>
Timing of revenue and recognition:				
At time services are rendered	\$ 4,663	\$ 959	\$ 1,020	\$ 6,642
Services transferred over time	5,598	1,271	1,566	8,435
Total	<u>\$ 10,261</u>	<u>\$ 2,230</u>	<u>\$ 2,586</u>	<u>\$ 15,077</u>
Year Ended December 31, 2022				
	Midwest	Southeast	Southwest	Total
Hospital	\$ 5,210	\$ 1,089	\$ 1,294	\$ 7,593
Clinic	3,404	844	961	5,209
Senior Care and Nursing Home	15	—	—	15
Other	62	1	—	63
Total patient care service revenue	8,691	1,934	2,255	12,880
External lab	901	—	—	901
Total medical service revenue	<u>\$ 9,592</u>	<u>\$ 1,934</u>	<u>\$ 2,255</u>	<u>\$ 13,781</u>
Timing of revenue and recognition:				
At time services are rendered	\$ 4,367	845	961	\$ 6,173
Services transferred over time	5,225	1,089	1,294	7,608
Total	<u>\$ 9,592</u>	<u>\$ 1,934</u>	<u>\$ 2,255</u>	<u>\$ 13,781</u>

Hospital revenue includes a variety of services mainly covering inpatient procedures requiring overnight stays or outpatient operations that require anesthesia or use of complex diagnostic and surgical equipment, as well as emergency care for traumas and other critical conditions. Clinic revenue includes services mainly focused on the care of outpatients covering primary and specialty health care needs. The Clinic's practice is to record certain radiology, pathology, and other hospital related services in the Midwest region as clinic revenue in the amount of \$1,130 and \$1,024 for the years ended December 31, 2023 and 2022, respectively. Examples of revenue at the time services are rendered include clinical services, lab and transport, and services transferred over time include hospital and senior care revenue.



## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

---

#### Note 3. Medical Service Revenue (Continued)

The composition of medical service revenue by payor for the years ended December 31 is as follows:

	2023	2022
Medicare	\$ 4,029	\$ 3,634
Medicaid	561	565
Contract	8,853	7,916
Other, including self-pay	1,634	1,666
Total	<u>\$ 15,077</u>	<u>\$ 13,781</u>

The Clinic's practice is to assign a patient to the primary payor and not reflect other uninsured balances (for example, coinsurance and deductibles) as self-pay. Therefore, the payors listed above contain patient responsibility components, such as coinsurance and deductibles.

#### Financing component:

The Clinic has elected the practical expedient allowed under FASB ASU 2014-09, *Revenue from Contracts with Customers (Topic 606-10-32-18)* and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Clinic's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Clinic does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

#### Note 4. Fair Value Measurements

The Clinic holds certain financial instruments that are required to be measured at fair value on a recurring basis. The valuation techniques used to measure fair value under the *Fair Value Measurement (Topic 820)* of the FASB ASC are based upon observable and unobservable inputs. The standard establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

**Level 1:** Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

**Level 2:** Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the same term of the financial instrument.

**Level 3:** Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instruments categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers or activity within Levels for the years ended December 31, 2023 and 2022.

**Mayo Clinic**

**Notes to Consolidated Financial Statements (In Millions)**

**Note 4. Fair Value Measurements (Continued)**

The following tables present the financial instruments carried at fair value as of December 31, 2023 and 2022, on the consolidated statements of financial position categorized by the valuation hierarchy and NAV:

	December 31, 2023				Total Fair Value
	Level 1	Level 2	Level 3	NAV	
<b>Assets:</b>					
Securities lending collateral	\$ 10	\$ —	\$ —	\$ —	\$ 10
<b>Investments:</b>					
Cash and cash equivalents	\$ 1,137	\$ 66	\$ —	\$ —	\$ 1,203
<b>Fixed-income securities:</b>					
U.S. government	\$ —	\$ 1,969	\$ —	\$ —	\$ 1,969
U.S. government agencies	\$ —	\$ 840	\$ —	\$ —	\$ 840
U.S. corporate	\$ —	\$ 918	\$ —	\$ —	\$ 918
Foreign	\$ —	\$ 51	\$ —	\$ —	\$ 51
<b>Common and preferred stocks:</b>					
U.S.	\$ 1,391	\$ —	\$ —	\$ —	\$ 1,391
Foreign	\$ 858	\$ —	\$ 20	\$ —	\$ 878
<b>Funds:</b>					
Fixed income	\$ 398	\$ —	\$ —	\$ —	\$ 398
Equities	\$ 1,107	\$ 716	\$ —	\$ —	\$ 1,823
<b>Less securities under lending agreement</b>					
	\$ (86)	\$ —	\$ —	\$ —	\$ (86)
Investments at NAV	\$ —	\$ —	\$ —	\$ 9,363	\$ 9,363
Total investments	\$ 4,805	\$ 4,560	\$ 20	\$ 9,363	\$ 18,748
<b>Investments under securities lending agreement</b>					
	\$ 86	\$ —	\$ —	\$ —	\$ 86
<b>Other long-term assets:</b>					
Trust receivables	\$ 69	\$ 29	\$ 120	\$ —	\$ 218
Technology-based ventures	\$ —	\$ —	\$ 268	\$ —	\$ 268
Total other long-term assets	\$ 69	\$ 29	\$ 388	\$ —	\$ 486
Total assets at fair value	\$ 4,970	\$ 4,589	\$ 408	\$ 9,363	\$ 19,330
<b>Liabilities:</b>					
Securities lending payable	\$ 10	\$ —	\$ —	\$ —	\$ 10
Total liabilities at fair value	\$ 10	\$ —	\$ —	\$ —	\$ 10

**Mayo Clinic**

**Notes to Consolidated Financial Statements (In Millions)**

**Note 4. Fair Value Measurements (Continued)**

	December 31, 2022				Total Fair Value
	Level 1	Level 2	Level 3	NAV	
<b>Assets:</b>					
Securities lending collateral	\$ 3	\$ —	\$ —	\$ —	\$ 3
<b>Investments:</b>					
Cash and cash equivalents	1,258	72	—	—	1,330
<b>Fixed-income securities:</b>					
U.S. government	—	1,956	—	—	1,956
U.S. government agencies	—	711	—	—	711
U.S. corporate	—	836	—	—	836
Foreign	—	58	—	—	58
<b>Common and preferred stocks:</b>					
U.S.	942	—	—	—	942
Foreign	646	—	20	—	666
<b>Funds:</b>					
Fixed income	327	—	—	—	327
Equities	1,049	662	—	—	1,711
Less securities under lending agreement	(68)	—	—	—	(68)
Investments at NAV	—	—	—	8,719	8,719
Total investments	4,154	4,295	20	8,719	17,188
Investments under securities lending agreement	68	—	—	—	68
<b>Other long-term assets:</b>					
Trust receivables	65	27	112	—	204
Technology-based ventures	—	—	176	—	176
Total other long-term assets	65	27	288	—	380
Total assets at fair value	\$ 4,290	\$ 4,322	\$ 308	\$ 8,719	\$ 17,639
<b>Liabilities:</b>					
Securities lending payable	\$ 3	\$ —	\$ —	\$ —	\$ 3
Total liabilities at fair value	\$ 3	\$ —	\$ —	\$ —	\$ 3

The following is a description of the Clinic's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets and liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers. Level 3 primarily consists of trusts recorded at fair value based on the underlying value of the assets in the trust or discounted cash flow of the expected payment streams.

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

The trusts reported as Level 3 are primarily perpetual trusts managed by third parties invested in stocks, mutual funds, and fixed-income securities that are traded in active markets with observable inputs and, since the Clinic will never receive the trust assets, these perpetual trusts are reported as Level 3. In addition, technology-based ventures, composed primarily of shares in start-up companies, are recorded at fair value based on inputs relying on factors such as the financial performance of the company, sales performance, financial projections, sales projections, management representation, industry developments, market analysis, and any other pertinent factors that would affect the fair value or based on the quoted price of an otherwise identical unrestricted security of the same issuer, adjusted for the effect of the restriction.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Clinic believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2023, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 4,254	\$ 388	Monthly to annually	30–90 days
Private partnerships (b)	5,109	2,043		
Total alternative investments	<u>\$ 9,363</u>	<u>\$ 2,431</u>		

At December 31, 2022, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,705	\$ 194	Monthly to annually	30–90 days
Private partnerships (b)	5,014	1,744		
Total alternative investments	<u>\$ 8,719</u>	<u>\$ 1,938</u>		

(a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry “lockup” restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly, or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.

**Notes to Consolidated Financial Statements (In Millions)**

---

**Note 4. Fair Value Measurements (Continued)**

(b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate, and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Clinic's ownership interest in partners' capital. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

From time to time, the Clinic invests directly in certain derivative contracts that do not qualify for hedge accounting and are recorded at fair value in investments. Changes in fair value are reported as a component of net unrealized gains or losses in the investment returns. These contracts are used in the Clinic's investment management program to minimize certain investment risks. During the years ended December 31, 2023 and 2022, the realized and unrealized loss from derivative contracts was not significant.

The Clinic uses various external investment managers to diversify the investments. The largest allocation to any investment strategy manager as of December 31, 2023 and 2022 was \$881 (6.3 percent) and \$801 (6.3 percent), respectively.

The Clinic is required to maintain funds held by trustees under bond indentures and other arrangements. The trustee-held investments, which primarily consist of mutual funds, were \$1,142 and \$976, respectively, at December 31, 2023 and 2022, which includes segregated investments for deferred compensation plans of \$1,129 and \$929 at December 31, 2023 and 2022, respectively.

At December 31, 2023 and 2022, cash and mutual funds included segregated investments owned by Mayo Foundation for Medical Education and Research, a wholly owned subsidiary of the Clinic, for gift annuity reserves of \$116 and \$101, respectively.

The Clinic had internally designated investment balances of \$3,181 and \$2,978 at December 31, 2023 and 2022, respectively, for research, education, and capital replacement and expansion.

## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

---

#### Note 5. Investments in Unconsolidated Entities

The Clinic holds certain investments in unconsolidated entities accounted for in accordance with FASB Subtopic 323, *Investments - Equity Method and Joint Ventures*. The investments are presented as other long-term assets in the consolidated statements of financial position. The Clinic's interest in the investment income is reflected in the accompanying consolidated statements of operations.

The following table presents investments in unconsolidated entities:

	<b>Ownership Percentage as of December 31, 2023</b>	<b>Carrying Value as of December 31, 2023</b>	<b>Carrying Value as of December 31, 2022</b>
Sheikh Shakhbout Medical City	25%	\$ 157	\$ 155
Other investees	Various	\$ 7	\$ 59

The Clinic entered into a joint venture agreement with Abu Dhabi Health Services Company PJSC (SEHA) to operate Sheikh Shakhbout Medical City (SSMC), a 741-bed hospital in the United Arab Emirates in November 2019. In addition to the joint venture agreement, the Clinic entered into a hospital expertise agreement, brand license agreement, and research contribution agreement with SSMC. The joint venture had an initial commitment period of twenty years which would have been extended by ten years if neither party terminated at the conclusion of the initial commitment period. The Clinic had a \$150 conditional pledge from Sheikh Shakhbout Medical City at December 31, 2023 and 2022. SEHA has agreed to acquire the Clinic's interest in SSMC with the transaction successfully closing in the first quarter of 2024. As part of this transaction, the parties also terminated the joint venture and related agreements.

The summarized financial position and results of operations for significant entities accounted for under the equity method as of and for the years ended consisted of the following:

	<u>2023</u>		<u>2022</u>	
<b>As of December 31</b>				
Total assets	\$	842	\$	920
Total liabilities	\$	236	\$	222
Partners equity/net assets	\$	842	\$	698
<b>Year Ended December 31</b>				
Total revenue	\$	586	\$	524
Gain (loss) from current activities	\$	4	\$	(64)

#### Note 6. Securities Lending

The Clinic has an arrangement with its investment custodian to lend Clinic securities to approved brokers in exchange for a fee. Among other provisions that limit the Clinic's risk, the securities lending agreement specifies that the custodian is responsible for lending securities and obtaining adequate collateral from the borrower. Collateral is limited to cash, government securities, and irrevocable letters of credit. Investments are loaned to various brokers and are returnable on demand. In exchange, the Clinic receives collateral. The cash collateral is shown as both an asset and a liability on the consolidated statements of financial position.

Notes to Consolidated Financial Statements (In Millions)

**Note 6. Securities Lending (Continued)**

At December 31, 2023 and 2022, the aggregate market value of securities on loan under securities lending agreements totaled \$86 and \$68, respectively, and the total value of the collateral supporting the securities was \$90 and \$70, respectively, which represents 104% and 103% of the value of the securities on loan at December 31, 2023 and 2022. The cash portion of the collateral supporting the securities as of December 31, 2023 and 2022 was \$10 and \$3, respectively. The cash portion is presented in other current assets and other current liabilities in the consolidated statements of financial position. Noncash collateral provided to the Clinic is not recorded in the consolidated statements of financial position, as the collateral may not be sold or repledged. The Clinic's claim on such collateral is limited to the market value of loaned securities. In the event of nonperformance by the other parties to the securities lending agreements, the Clinic could be exposed to a loss.

**Note 7. Property, Plant, and Equipment, Net**

Property, plant, and equipment, net, at December 31 consisted of the following:

	2023	2022
Land	\$ 589	\$ 580
Buildings and improvements	7,663	7,322
Furniture and equipment	4,693	4,633
	<u>12,945</u>	<u>12,535</u>
Accumulated depreciation and amortization	(7,618)	(7,414)
	5,327	5,121
Construction in progress	1,104	766
Total property, plant, and equipment	<u>\$ 6,431</u>	<u>\$ 5,887</u>

The above costs and accumulated depreciation include costs for capitalized software, including costs capitalized in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Topic 350)* of the FASB ASC. The total cost for capitalized software was \$771 and \$893 at December 31, 2023 and 2022, respectively. The total accumulated amortization was \$582 and \$647 at December 31, 2023 and 2022, respectively. Amortization expense for capitalized software was \$67 and \$74 for 2023 and 2022, respectively.

**Note 8. Income Taxes**

Most of the income received by the Clinic and its subsidiaries is exempt from taxation under Section 501(a) of the Internal Revenue Code. Some of its subsidiaries are taxable entities, and some of the income received by otherwise exempt entities is subject to taxation as unrelated business income. The Clinic and its subsidiaries file income tax returns in the U.S., including federal and various state returns, as well as certain foreign jurisdictions. The statutes of limitations for tax years 2020 through 2022 remain open in major U.S. taxing jurisdictions in which the Clinic and subsidiaries are subject to taxation.

The Internal Revenue Service (IRS) performed an examination of the tax and information returns of the Clinic and two subsidiaries and ultimately assessed \$12 in taxes for years 2003-2012. The results of this audit were litigated in the U.S. District Court. On August 6, 2019, the Court issued a summary judgment in favor of the Clinic. The IRS appealed this decision and on May 13, 2021, the Eighth Circuit Court of Appeals reversed the summary judgment and remanded the case to the U.S. District Court for trial. The case was tried in 2022 and the U.S. District Court issued a judgment in favor of the Clinic on December 9, 2022. The IRS disagreed with this ruling and filed an appeal with the Eighth Circuit Court of Appeals on September 1, 2023. A Request for Oral Argument was filed with the Court, but no date for the hearing has

## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

#### Note 8. Income Taxes (Continued)

been assigned. No adjustment has been made to unrecognized tax benefits as the issue has not been definitively resolved at this time.

The Clinic has reduced the reserve for uncertain tax positions by \$2, including interest and penalties, during the year ended December 31, 2023. As of December 31, 2023 and 2022, the reserve totaled \$9 and \$11, respectively. It is not anticipated that a significant change in the reserve will occur over the next 12 months.

The Clinic's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The components of tax expense are as follows:

	Year ended December 31	
	2023	2022
Current—federal	\$ 28	\$ 23
Current—state	7	6
	<u>35</u>	<u>29</u>
Deferred—U.S. domestic	6	(6)
Total	<u>\$ 41</u>	<u>\$ 23</u>

Cash payments for income taxes were \$62 and \$33 for the years ended December 31, 2023 and 2022, respectively.

The Clinic records deferred income taxes due to temporary differences between financial reporting and tax reporting for certain assets and liabilities of its taxable activities. The following is a summary of the components of deferred taxes as of December 31:

	2023	2022
Deferred compensation	\$ 9	\$ 9
Pension	—	—
Postretirement benefits	1	2
Net operating loss	2	6
Other	4	6
Total deferred tax asset	<u>16</u>	<u>23</u>
Deferred tax liability	(2)	(2)
Valuation allowance	(10)	(10)
Net deferred tax asset	<u>\$ 4</u>	<u>\$ 11</u>

The Clinic had federal net operating losses of \$11 and \$20 at December 31, 2023 and 2022, respectively.

The Tax Cuts and Jobs Act (TCJA), enacted on December 22, 2017 repealed Net Operating Loss (NOL) carrybacks while permitting indefinite carryforwards. The Coronavirus Aid, Relief and Economic Security Act enacted on March 27, 2020 temporarily suspended TCJA repeal of NOL carrybacks allowing for NOLs arising in tax years beginning after December 31, 2017 and before January 1, 2021 to be carried back to the five taxable years preceding the taxable year of such loss. During 2023 the Clinic was able to utilize



**Note 8. Income Taxes (Continued)**

\$9 of the NOLs arising in tax years beginning after December 31, 2018 and before January 1, 2022. Of the remaining NOLS, \$11 will be carried forward.

## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

#### Note 9. Financing

Long-term debt at December 31 consisted of the following:

		2023	2022
City of Rochester, Minnesota Revenue Bonds issued in various series, subject to variable interest rates to a maximum rate of 15.00% (the average rate was 3.47% in 2023 and 1.27% in 2022), principal due in varying amounts from 2028 through 2052	Variable	\$ 545	\$ 545
City of Rochester, Minnesota Revenue Bonds originally issued at variable interest rate, converted in 2017 to fixed interest rate of 2.20% based on a provision to increase the rate if the federal tax rate is decreased, the rate has been adjusted to 2.67% effective January 1, 2018 through 2027, principal due in varying amounts from 2022 through 2032	Fixed	127	163
City of Rochester, Minnesota Revenue Bonds originally issued with fixed interest rate of 4.74%, converted in 2020 to fixed interest rate of 1.54% until 2030, principal due in varying amounts from 2033 through 2038	Fixed	130	130
City of Rochester, Minnesota Revenue Bonds issued in various series with fixed rate of interest of 4.00%, principal due in varying amounts from 2044 through 2048	Fixed	200	200
City of Rochester, Minnesota Health Care Facilities Revenue Refunding Bonds, series 2016B, issued with fixed interest rate of 5.00%, an effective rate of 2.97% in 2023 and 2022 after amortization of premium, principal due in varying amounts from 2029 through 2036 (unamortized premium of \$42 in 2023 and \$46 in 2022)	Fixed	220	220
City of Rochester, Minnesota Health Care Facilities Revenue Bonds, series 2022, issued in various series with fixed interest rates ranging from 3.25% to 5.00%, an effective rate of 3.74% in 2023 and 2022 after amortization of premium principal due in varying amounts from 2039 through 2057 (unamortized net premium of \$16 in 2023 and 2022)	Fixed	289	289
Industrial Development Authority of the City of Phoenix, Arizona issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 3.51% in 2023 and 0.96% in 2022), principal due in varying amounts from 2048 through 2052	Variable	180	180
City of Jacksonville, Florida Health Care Facilities Revenue Refunding Bonds, series 2016, issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 3.55% in 2023 and 1.32% in 2022), principal due in varying amounts from 2033 through 2047	Variable	125	125
Mayo Clinic Taxable Bonds issued with fixed interest rates ranging from 3.20% to 4.13%, principal due in varying amounts from 2039 through 2061	Fixed	1,450	1,450
Fixed-rate notes and bonds, payable to financial companies, interest rates at 1.80% to 4.71%, principal due in varying amounts from 2025 through 2062	Fixed	1,115	1,115
The Industrial Development Authority of the City of Phoenix, Arizona Health Care Facilities Revenue Bonds, series 2022, issued in various series with fixed interest rates ranging from 3.75% to 4.00%, an effective rate of 3.80% in 2023 and 2022 after amortization of premium, principal due in varying amounts from 2053 to 2057 (unamortized net premium of \$3 in 2023 and 2022)	Fixed	298	298
Other notes payable		11	12
Unamortized discounts and premiums, net		61	66
Debt issuance cost		(15)	(16)
		<u>4,736</u>	<u>4,777</u>
Long-term variable-rate debt classified as current		(620)	(620)
Current maturities included in other current liabilities		(18)	(36)
Long-term debt, net of current portion		<u>\$ 4,098</u>	<u>\$ 4,121</u>

Notes to Consolidated Financial Statements (In Millions)

---

**Note 9. Financing (Continued)**

The Clinic's outstanding revenue bond issues are limited obligations of various issuing authorities payable solely by the Clinic pursuant to loan agreements between the borrowing entities and the issuing authorities. Under various financing agreements, the Clinic must meet certain operating and financial performance covenants.

At December 31, 2023, the \$850 of variable-rate bonds consisted of variable-rate demand revenue bonds. In conjunction with the issuance of the variable-rate demand revenue bonds, the Clinic has entered into various bank standby purchase and credit agreements in the amount of \$230 which will expire in January 2025. Under the terms of these agreements, the bank will make liquidity loans to the Clinic in the amount necessary to purchase a portion of the variable-rate demand revenue bonds if not remarketed. The liquidity loans would be payable over a three- to five-year period, with the first payment due after December 31, 2024. The Clinic has provided self-liquidity for the remaining \$620 of variable-rate demand revenue bonds, which have been classified as current in the accompanying consolidated statements of financial position.

The \$220 fixed-rate revenue bonds Series 2016B are not callable. The remaining fixed-rate interest revenue bonds are callable from 2024 to 2058 at the option of the Clinic, at a redemption price of 100 percent of the principal amount or at a price based on U.S. Treasury rates at the time of redemption.

On April 12, 2022 the Clinic issued fixed rate bonds in the amount of \$587 (\$200 refunding and \$387 new debt issuance) at various coupon rates yielding 3.76 percent to maturity. The bonds are due in 2057 and the new debt will be used for construction projects.

On May 5, 2022, the Clinic entered into a private placement debt agreement with an insurance company for \$200 at 3.26 percent maturing in 2058. The funds will be used for general corporate purposes.

The following are scheduled maturities of long-term debt for each of the next five years, assuming the variable-rate demand revenue bonds are remarketed and the standby purchase agreements are renewed. As described above, if such bonds are not remarketed, \$620 may be due in 2024 and \$230 may be due in years from 2025 to 2029.

Years ending December 31:

2024	\$	18
2025		105
2026		5
2027		105
2028		45

Interest payments on long-term debt, net of amounts capitalized for 2023 and 2022, totaled \$154 and \$132, respectively. The amount of interest capitalized, net of related interest income, was \$12 and \$8 during 2023 and 2022. Interest expense totaled \$157 and \$144 for 2023 and 2022, respectively.

At December 31, 2023 and 2022, the Clinic had unsecured lines of credit available with banks that totaled \$530, with varying renewable terms and interest up to 2.50 percent over various published rates. There were no amounts drawn during the years ended December 31, 2023 and 2022.

## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

---

#### Note 10. Leases

At December 31, 2023 and 2022, the Clinic had operating and finance leases for facilities and certain equipment with lease terms ranging from 1 to 20 years, with some options to extend up to five years or terminate within one year.

Total lease expense for the years ended December 31 consisted of the following:

	2023	2022
Operating lease expense	\$ 30	\$ 34
Finance lease expense:		
Amortization of right-of-use assets	\$ 6	\$ 6
Interest on lease liabilities	1	1
Total finance lease expense	\$ 7	\$ 7
Short-term lease expense	\$ 48	\$ 28

Consolidated supplemental cash flow information related to leases as of December 31 consisted of the following:

	2023	2022
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 57	\$ 60
Operating cash flows for finance leases	\$ 1	\$ 1
Financing cash flows for finance leases	\$ 7	\$ 7
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	\$ 25	\$ 18
Finance leases	\$ 24	\$ 4

Consolidated supplemental statement of financial position information related to leases as of the years ended December 31 consisted of the following:

	2023	2022
Operating leases:		
Right-of-use assets	\$ 122	\$ 141
Other current liabilities	\$ 22	\$ 23
Other long-term liabilities	127	123
Total operating lease liabilities	\$ 149	\$ 146

**Mayo Clinic**

**Notes to Consolidated Financial Statements (In Millions)**

**Note 10. Leases (Continued)**

	2023	2022
Finance leases:		
Property, plant, and equipment, gross	\$ 76	\$ 57
Accumulated depreciation	38	36
Property, plant, and equipment, net	<u>\$ 38</u>	<u>\$ 21</u>
Other current liabilities	\$ 9	\$ 6
Other long-term liabilities	27	—
Total finance lease liabilities	<u>\$ 36</u>	<u>\$ 6</u>
Weighted average remaining lease years:		
Operating leases	8.94	9.22
Finance leases	5.39	4.14
Weighted average discount rate:		
Operating leases	3.44 %	3.35 %
Finance leases	3.38 %	2.98 %

Maturities of lease liabilities for the next five years and thereafter consist of the following:

	Operating	Finance
2024	\$ 30	\$ 10
2025	23	7
2026	21	6
2027	19	5
2028	17	5
Thereafter	68	6
Minimum lease payments	<u>178</u>	<u>39</u>
Less amount representing interest	29	3
Net minimum lease payments	<u>\$ 149</u>	<u>\$ 36</u>

**Mayo Clinic**

**Notes to Consolidated Financial Statements (In Millions)**

---

**Note 11. Board-Designated Funds**

Board-designated funds are subject to expenditure for the following purposes for the years ended December 31:

	2023	2022
Research	\$ 1,581	\$ 1,498
Education	327	312
Buildings and equipment	3	3
Charity care	13	12
Clinical	164	162
Other	1,093	991
Total designation for specified purpose	<u>\$ 3,181</u>	<u>\$ 2,978</u>

At December 31, board designated funds were classified as follows:

	2023	2022
Quasi-endowments	\$ 2,967	\$ 2,830
Professional liability reserve	185	119
Other	\$ 29	\$ 29
Total	<u>\$ 3,181</u>	<u>\$ 2,978</u>

**Mayo Clinic****Notes to Consolidated Financial Statements (In Millions)**

---

**Note 12. Net Assets with Donor Restrictions**

The Clinic receives contributions in support of research, education, and clinical activities. Net assets with donor restrictions were available for the following purposes at December 31:

	2023	2022
Subject to expenditure for specified purposes:		
Research	\$ 686	\$ 582
Education	59	59
Buildings and equipment	180	245
Charity care	32	30
Clinical	89	74
Other	38	30
Total expenditure for specified purposes	<u>1,084</u>	<u>1,020</u>
Subject to passage of time:		
Pledges and trusts	<u>682</u>	<u>642</u>
Endowments:		
Perpetual in nature:		
Research	1,263	1,233
Education	355	304
Charity care	14	14
Clinical	224	222
Other	50	31
Pledges and trusts	269	270
Total perpetual in nature	<u>2,175</u>	<u>2,074</u>
Subject to endowment spending policy:		
Research	824	745
Education	370	342
Charity care	52	48
Clinical	166	152
Other	43	40
Total subject to endowment spending policy	<u>1,455</u>	<u>1,327</u>
Total endowments	<u>3,630</u>	<u>3,401</u>
Total net assets with donor restrictions	<u>\$ 5,396</u>	<u>\$ 5,063</u>

Notes to Consolidated Financial Statements (In Millions)

**Note 12. Net Assets with Donor Restrictions (Continued)**

Net assets were released from donor restrictions as expenditures were made, which satisfied the following restricted purposes for the years ended December 31:

	2023	2022
Research	\$ 200	\$ 180
Education	30	25
Buildings and equipment	181	36
Other	31	96
Total net assets released from donor restrictions	<u>\$ 442</u>	<u>\$ 337</u>

**Note 13. Endowment**

The Clinic's endowment consists of approximately 2,400 individual funds established for a variety of purposes. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments (quasi-endowments). Net assets associated with endowment funds, including quasi endowments, are classified and reported based on the existence or absence of donor-imposed restrictions. The Board of Trustees retains the right to re-designate quasi endowments for other purposes.

The Board of Trustees of the Clinic has interpreted the Minnesota State Prudent Management of Institutional Funds Act (SPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. As a result of this interpretation, the Clinic retains in perpetuity: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the perpetual endowment, and (c) accumulations to the perpetual endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

In accordance with SPMIFA, the Clinic considers the following factors in making a determination to appropriate or accumulate donor-restricted funds:

1. The duration and preservation of the fund
2. The purposes of the Clinic and the donor-restricted endowment fund
3. General economic conditions
4. The possible effects of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. Other resources of the Clinic
7. The investment policies of the Clinic

The Clinic has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment, while seeking to maintain purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Clinic must hold in perpetuity or for a donor-specified period(s), as well as quasi-endowments. Under this policy, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce a real return, net of inflation and investment management costs, of at least five percent over the long term. Actual returns in any given year may vary from this amount.

To satisfy its long-term rate-of-return objectives, the Clinic relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Clinic targets a diversified asset allocation that places a greater



**Mayo Clinic**

**Notes to Consolidated Financial Statements (In Millions)**

**Note 13. Endowment (Continued)**

emphasis on equity-based and alternative investments to achieve its long-term objective within prudent risk constraints.

The Clinic has a policy of appropriating for distribution each year five percent of its endowment fund's moving average fair value over the prior 36 months as of September 30 of the preceding year in which the distribution is planned. In establishing this policy, the Clinic considered the long-term expected return on its endowment. Accordingly, over the long term, the Clinic expects the current spending policy to allow its endowment to grow at an average of the long-term rate of inflation. This is consistent with the Clinic's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specific term, as well as to provide additional real growth through new gifts and investment return.

At December 31, 2023, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 3,630	\$ 3,630
Quasi-endowments	2,967	—	2,967
Total funds	<u>\$ 2,967</u>	<u>\$ 3,630</u>	<u>\$ 6,597</u>

Changes in endowment net assets for the year ended December 31, 2023, consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 2,830	\$ 3,401	\$ 6,231
Investment return:			
Investment income	39	44	83
Net appreciation (realized and unrealized)	204	225	429
Total investment return	<u>243</u>	<u>269</u>	<u>512</u>
Contributions	<u>—</u>	<u>102</u>	<u>102</u>
Appropriation of endowment assets for expenditure	<u>(167)</u>	<u>(142)</u>	<u>(309)</u>
Other changes:			
Transfers to create quasi-endowments	61	—	61
Endowment net assets, end of year	<u>\$ 2,967</u>	<u>\$ 3,630</u>	<u>\$ 6,597</u>

**Mayo Clinic****Notes to Consolidated Financial Statements (In Millions)****Note 13. Endowment (Continued)**

At December 31, 2022, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 3,401	\$ 3,401
Quasi-endowments	2,830	—	2,830
Total funds	<u>\$ 2,830</u>	<u>\$ 3,401</u>	<u>\$ 6,231</u>

Changes in endowment net assets for the year ended December 31, 2022, consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 3,218	\$ 3,722	\$ 6,940
Investment return:			
Investment income	32	34	66
Net depreciation (realized and unrealized)	(330)	(356)	(686)
Total investment return	<u>(298)</u>	<u>(322)</u>	<u>(620)</u>
Contributions	—	128	128
Appropriation of endowment assets for expenditure	<u>(146)</u>	<u>(127)</u>	<u>(273)</u>
Other changes:			
Transfers to create quasi endowments	56	—	56
Endowment net assets, end of year	<u>\$ 2,830</u>	<u>\$ 3,401</u>	<u>\$ 6,231</u>

**Note 14. Promises to Give**

At December 31, outstanding pledges from various corporations, foundations, and individuals, included in other receivables and other long-term assets, were as follows:

	2023	2022
Pledges due:		
In less than one year	\$ 325	\$ 319
In one to five years	311	367
In more than five years	65	64
	<u>701</u>	<u>750</u>
Allowance for uncollectible pledges and discounts	(30)	(38)
Total	<u>\$ 671</u>	<u>\$ 712</u>

Notes to Consolidated Financial Statements (In Millions)

**Note 14. Promises to Give (Continued)**

Estimated cash flows from pledge receivables due after one year are discounted using a risk-adjusted rate, ranging from 1 percent to 6 percent, that is commensurate with the pledges due dates and established in the year the pledge is received.

The Clinic has received interests in various trusts, primarily split-interest, which are included in other long-term assets. The trusts are recorded at fair value, based on the underlying value of the assets in the trust or discounted cash flow using a risk-adjusted discount rate of 5.77 percent and 3.12 percent at December 31, 2023 and 2022, respectively. During the years ended December 31, 2023 and 2022, there were no contributions recorded related to the split-interest trusts. The balance of the expected payment streams was \$218 and \$204 at December 31, 2023 and 2022, respectively.

**Note 15. Functional Expenses**

The consolidated financial statements present certain expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. Benefits and payroll taxes are allocated based on factors of either salary expense or hours worked. Overhead costs that include professional services, office expenses, information technology, interest, insurance, and other similar expenses are allocated based on a variety of factors, including revenues, hours worked, and salary expense. Costs related to space, including occupancy, depreciation and amortization, and property taxes, are allocated on a square footage basis.

The expenses reported in the consolidated statements of activities for the years ended December 31, 2023 and 2022 supported the following programs and functions:

		2023								
		Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	Total expenses	
Salaries and benefits	\$	7,982	\$ 190	\$ 728	\$ 392	\$ 290	\$ 28	\$ 57	\$	9,667
Supplies and services		4,231	1,132	299	94	46	12	136		5,950
Depreciation and amortization		552	8	69	13	16	1	4		663
Facilities		311	6	20	14	34	1	2		388
Finance and investment		168	10	20	2	2	—	(10)		192
<b>Total</b>	<b>\$</b>	<b>13,244</b>	<b>\$ 1,346</b>	<b>\$ 1,136</b>	<b>\$ 515</b>	<b>\$ 388</b>	<b>\$ 42</b>	<b>\$ 189</b>	<b>\$</b>	<b>16,860</b>

		2022								
		Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	Total expenses	
Salaries and benefits	\$	7,664	\$ 197	\$ 690	\$ 343	\$ 210	\$ 19	\$ 47	\$	9,170
Supplies and services		3,789	1,073	280	72	62	11	90		5,377
Depreciation and amortization		512	8	69	10	22	1	2		624
Facilities		268	5	18	12	44	1	2		350
Finance and investment		152	9	18	2	2	—	(9)		174
<b>Total</b>	<b>\$</b>	<b>12,385</b>	<b>\$ 1,292</b>	<b>\$ 1,075</b>	<b>\$ 439</b>	<b>\$ 340</b>	<b>\$ 32</b>	<b>\$ 132</b>	<b>\$</b>	<b>15,695</b>

## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

#### Note 16. Employee Benefit Programs

The Clinic serves as plan sponsor for several defined benefit pension funds and other postretirement benefits.

Included in other changes in unrestricted net assets at December 31, 2023 and 2022, are the following amounts, respectively, that have not yet been recognized in net periodic cost: unrecognized actuarial losses of \$620 and \$137 and unrecognized prior service benefit of \$102 and \$63. Actuarial losses are amortized as a component of net periodic pension cost, only if the losses exceed ten percent of the greater of the projected benefit obligation or the fair value of plan assets. Unrecognized prior service benefits are amortized on a straight-line basis over the estimated life of plan participants.

Changes in plan assets and benefit obligations recognized in unrestricted net assets during 2023 and 2022 included the following:

	2023	2022
Current-year actuarial (loss) gain	\$ (482)	\$ 2,659
Amortization of actuarial loss	(1)	246
Current-year prior service cost	(116)	—
Amortization of prior service credit	(49)	(46)
Pension and other postretirement benefit adjustments	<u>\$ (648)</u>	<u>\$ 2,859</u>

#### Pension plans:

**Obligations and funded status:** The following is a summary of the changes in the benefit obligation and plan assets, the resulting funded status of the qualified and nonqualified pension plans, and accumulated benefit obligation as of and for the years ended December 31:

	2023	2022
Change in projected benefit obligation:		
Benefit obligation, beginning of year	\$ 7,809	\$ 12,194
Service cost	383	690
Interest cost	436	370
Actuarial loss (gain)	572	(4,381)
Benefits paid	(424)	(1,058)
Plan amendments	113	—
Settlements	—	(6)
Estimated benefit obligation at end of year	<u>\$ 8,889</u>	<u>\$ 7,809</u>
Change in plan assets:		
Fair value of plan assets, beginning of year	\$ 9,965	\$ 11,903
Actual return on plan assets	878	(1,188)
Employer contributions	283	314
Benefits paid	(424)	(1,058)
Settlements	—	(6)
Fair value of plan assets at end of year	<u>\$ 10,702</u>	<u>\$ 9,965</u>

## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

#### Note 16. Employee Benefit Programs (Continued)

	2023	2022
Funded status of the plans	\$ 1,813	\$ 2,156
Accumulated benefit obligation	\$ (8,094)	\$ (7,361)

Amounts recognized in the consolidated statements of financial position consist of the following at December 31:

	2023	2022
Noncurrent assets	\$ 1,814	\$ 2,164
Noncurrent liabilities	\$ (1)	\$ (8)
Net amount recognized	\$ 1,813	\$ 2,156

Components of net periodic benefit cost are as follows for the years ended December 31:

	2023	2022
Service cost	\$ 383	\$ 690
Interest cost	436	370
Expected return on plan assets	(778)	(781)
Amortization of unrecognized:		
Prior service benefit	(50)	(50)
Net actuarial loss	—	226
Settlement	—	2
Net periodic benefit cost	\$ (9)	\$ 457

**Plan assets:** The largest of the pension funds is the Mayo Clinic Master Retirement Trust Plan, which holds \$10,574 of the \$10,702 in combined plan assets at December 31, 2023, and \$9,864 of the \$9,965 in combined plan assets at December 31, 2022. The investment policies described below apply to the Mayo Clinic Master Retirement Trust Plan (the Plan).

The Plan employs a global, multi-asset approach in managing its retirement plan assets. This approach is designed to maximize risk-adjusted returns over a long-term investment horizon, consistent with the nature of the pension liabilities being funded. The plan asset portfolio's target allocation for total return investment strategies, which include public equities, private equities, absolute return, and real assets, is 82.5 percent. The portfolio's target fixed-income exposure is 17.5 percent. The fixed-income exposure may include the use of long-term interest rate swap contracts structured to increase the portfolio's interest rate sensitivity and thereby provide a hedge of the plan liabilities resulting from falling long-term interest rates. Investments in private equities, real assets, and absolute return strategies are held to improve diversification and thereby enhance long-term, risk-adjusted returns. However, recognizing that these investments are not as liquid as publicly traded stocks and bonds, portfolio investment policies limit overall exposure to these assets. The portfolio's allocation to private equities and real assets is limited to a maximum of 35 percent (with a target allocation of 25 percent), and exposure to absolute return strategies is limited to a maximum of 30 percent (with a target of 25 percent). The Clinic reviews performance, asset allocation, and risk management reports for plan asset portfolios on a monthly basis.

## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

#### Note 16. Employee Benefit Programs (Continued)

The fair values of the Plan's assets at December 31, 2023, by asset category, are as follows:

Assets	Quoted Prices			NAV	Total
	in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)		
Cash and cash equivalents	\$ 208	\$ 23	\$ —	\$ —	\$ 231
Fixed income securities:					
U.S. government	—	110	—	—	110
U.S. government agencies	—	175	—	—	175
U.S. corporate	—	338	—	—	338
Foreign	—	28	—	—	28
Common and preferred stocks:					
U.S.	979	—	—	—	979
Foreign	595	—	—	—	595
Funds:					
Fixed income	127	—	—	—	127
Equities	94	673	—	—	767
Foreign	54	—	—	—	54
Investments at NAV	—	—	—	7,170	7,170
Total investments	\$ 2,057	\$ 1,347	\$ —	\$ 7,170	\$ 10,574

The fair values of the Plan's assets at December 31, 2022, by asset category, are as follows:

Assets	Quoted Prices			NAV	Total
	in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)		
Cash and cash equivalents	\$ 162	\$ 4	\$ —	\$ —	\$ 166
Fixed income securities:					
U.S. government	—	95	—	—	95
U.S. government agencies	—	155	—	—	155
U.S. corporate	—	316	—	—	316
Foreign	—	36	—	—	36
Common and preferred stocks:					
U.S.	777	—	—	—	777
Foreign	479	—	—	—	479
Funds:					
Fixed income	61	—	—	—	61
Equities	34	637	—	—	671
Foreign	47	1	—	—	48
Investments at NAV	—	—	—	7,060	7,060
Total investments	\$ 1,560	\$ 1,244	\$ —	\$ 7,060	\$ 9,864

Notes to Consolidated Financial Statements (In Millions)

**Note 16. Employee Benefit Programs (Continued)**

The following is a description of the Plan's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers in 2023 or 2022.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2023, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,693	\$ 270	Monthly to annually	30–90 days
Private partnerships (b)	3,477	1,453		
	<u>\$ 7,170</u>	<u>\$ 1,723</u>		

At December 31, 2022, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,493	\$ 116	Monthly to annually	30–90 days
Private partnerships (b)	3,567	1,369		
	<u>\$ 7,060</u>	<u>\$ 1,485</u>		

(a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry "lockup" restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period,

Notes to Consolidated Financial Statements (In Millions)

**Note 16. Employee Benefit Programs (Continued)**

liquidity is generally available monthly, quarterly, or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.

- (b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate, and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Plan's ownership interest in partners' capital. These investments cannot be redeemed with the funds. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

No plan assets are expected to be returned to the employer during 2024.

**Other postretirement benefits:**

**Obligations and funded status:** A summary of the changes in the benefit obligation and plan assets and the resulting funded status of the other postretirement plans is as follows as of and for the years ended December 31:

	2023	2022
Change in projected benefit obligation:		
Benefit obligation at beginning of year	\$ 867	\$ 1,138
Service cost	4	7
Interest cost	48	34
Plan participants contributions	42	41
Amendments	2	—
Medicare subsidy	3	2
Actuarial loss (gain)	10	(255)
Benefits paid	(107)	(100)
Estimated benefit obligation at end of year	<u>\$ 869</u>	<u>\$ 867</u>
Change in plan assets:		
Fair value of plan assets at beginning of year	\$ —	\$ —
Employer contributions	65	59
Plan participants contributions	42	41
Benefits paid	(107)	(100)
Fair value of plan assets at end of year	<u>\$ —</u>	<u>\$ —</u>
Funded status of the plan	<u>\$ (869)</u>	<u>\$ (867)</u>

Amounts recognized in the consolidated statements of financial position for postretirement benefits consist of the following at December 31:

	2023	2022
Current liabilities	\$ (57)	\$ (56)
Noncurrent liabilities	(812)	(811)
Net amount recognized	<u>\$ (869)</u>	<u>\$ (867)</u>



Notes to Consolidated Financial Statements (In Millions)

**Note 16. Employee Benefit Programs (Continued)**

Components of net periodic benefit cost for other postretirement benefits are as follows for the years ended December 31:

	2023	2022
Service cost	\$ 4	\$ 7
Interest cost	48	34
Amortization of:		
Unrecognized prior service benefit	1	4
Unrecognized net actuarial (gain) loss	(1)	20
Net periodic benefit cost for other postretirement benefits	<u>\$ 52</u>	<u>\$ 65</u>

The Clinic has concluded that the prescription drug benefits under its defined benefit postretirement plan are actuarially equivalent to Medicare Part D under the Medicare Modernization Act (the Act) and that the Clinic will receive the subsidy available under the Act.

The following reflects the expected future Medicare Part D subsidy receipts:

Years ending December 31:

2024	\$	3
2025		3
2026		3
2027		3
2028		3
2029–2033		16

Plan trend rates are the annual rates of increase expected for the benefits payable from the plan; these rates include health care cost trends plus the leveraging effect of plan design. The assumed plan trend rate is 5.50 percent.

**Pension and postretirement benefits:**

**Assumptions:** Weighted average assumptions used to determine pension and postretirement benefit obligations at the measurement date are as follows:

	Pension Benefits		Postretirement Benefits	
	2023	2022	2023	2022
Discount rate	5.43%	5.77%	5.42%	5.68%
Rate of compensation increase	3.67%	3.67%	—%	N/A

Notes to Consolidated Financial Statements (In Millions)

**Note 16. Employee Benefit Programs (Continued)**

Weighted-average assumptions used to determine net periodic pension and postretirement benefit cost are as follows:

	Pension Benefits		Postretirement Benefits	
	2023	2022	2023	2022
Discount rate	5.77%	3.12%	5.68%	3.04%
Expected long-term return on plan assets	7.50%	7.50%	N/A	N/A
Rate of compensation increase	3.70%	3.72%	N/A	N/A

The Clinic utilizes a building block approach in determining the expected long-term rate of return for its plan assets. First, historical data on individual asset class returns are studied. Next, the historical correlation among and between asset class returns is studied under both normal conditions and in times of market turbulence. Then, various mixes of asset classes are considered under multiple long-term investment scenarios. Finally, after considering liquidity concerns related to the use of certain alternative asset classes, the plan sponsor selects the portfolio blend that it believes will produce the highest expected long-term return on a risk-adjusted basis.

**Cash flows:**

**Contributions:** The Clinic expects to contribute \$280 to its pension plans in 2024.

**Estimated future benefit payments:** The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

	Pension Benefits	Postretirement Benefits
Years ending December 31:		
2024	\$ 541	\$ 59
2025	524	60
2026	534	61
2027	546	62
2028	558	63
2029–2033	2,962	320

In addition to the defined benefit plans, the Clinic sponsors various defined contribution benefit plans. Expense recognized by the Clinic for those plans was \$142 and \$131 for 2023 and 2022, respectively.

**Note 17. General and Professional Liability Insurance**

The Clinic insures substantially all general and professional liability risks through a combination of a wholly owned captive insurance company and self-insurance. The insurance program combines various levels of self-insured retention with excess commercial insurance coverage. Actuarial consultants have been retained to assist in the estimation of outstanding general and professional liability losses.

**Notes to Consolidated Financial Statements (In Millions)**

**Note 17. General and Professional Liability Insurance (Continued)**

The Clinic's general and professional liability as reported in the accompanying consolidated statements of financial position was \$164 and \$159 at December 31, 2023 and 2022, respectively. Provisions for the general and professional liability risks are based on an actuarial estimate of losses using the Clinic's actual loss data, adjusted for industry trends and current conditions, and considering an evaluation of claims by the Clinic's legal counsel. The provision includes estimates of ultimate costs for both reported claims and claims incurred but not reported.

Activity in the liability is summarized as follows for the years ended December 31:

	2023	2022
Balance, beginning of year	\$ 159	\$ 133
Incurred related to captive insurance company liability:		
Current year	35	30
Prior years	20	12
Total incurred	55	42
Paid related to captive insurance company liability:		
Current year	(6)	(1)
Prior years	(40)	(24)
Total paid	(46)	(25)
Net change in self-insurance liability	(4)	9
Balance, end of year	\$ 164	\$ 159

**Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities**

At December 31, other receivables consisted of the following:

	2023	2022
Pledges receivable	\$ 325	\$ 319
Grants receivable	173	145
Pharmacy receivable	74	58
Rebates receivable	73	34
Interest receivable	40	28
Royalty receivable	11	25
Other tax receivable	5	7
Other	86	143
Total other receivables	\$ 787	\$ 759

**Mayo Clinic****Notes to Consolidated Financial Statements (In Millions)**

---

**Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)**

At December 31, other current assets consisted of the following:

	2023	2022
Inventories	\$ 234	\$ 218
Prepaid expenses	148	166
Other	9	2
Total other current assets	<u>\$ 391</u>	<u>\$ 386</u>

At December 31, other long-term assets consisted of the following:

	2023	2022
Pension asset	\$ 1,814	\$ 2,164
Pledges receivable	346	393
Technology-based ventures	268	176
Oil and gas interests	259	199
Trust receivables	218	204
Investments in unconsolidated entities	164	214
Operating lease right-of-use asset	122	141
Prepaid maintenance	79	23
Notes receivable	69	29
Long-term portion of deferred tax asset	4	11
Other	85	77
Total other long-term assets	<u>\$ 3,428</u>	<u>\$ 3,631</u>

**Mayo Clinic****Notes to Consolidated Financial Statements (In Millions)****Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)**

At December 31, other current liabilities consisted of the following:

	2023	2022
Other taxes	\$ 92	\$ 87
Oil and gas liability	51	15
Current portion of long-term disability	50	49
Current portion of professional and general liability	49	43
Short-term disability	34	30
Real estate tax accrual	28	28
Refunds/recoupments	23	24
Operating lease liability	22	23
Accrued interest	22	20
Current maturities of long-term debt	18	36
Medicare settlements liability	12	13
Current portion of workers' compensation liability	12	11
Finance lease liability	9	6
Other	69	85
Total other current liabilities	<u>\$ 491</u>	<u>\$ 470</u>

At December 31, other long-term liabilities consisted of the following:

	2023	2022
Deferred compensation	\$ 1,129	\$ 929
Long-term disability	246	224
Operating lease liability	127	123
Deferred gain	126	135
Professional and general liability	115	116
Electronic medical record	96	96
Retirement community obligations	92	96
Gift annuities	67	65
Financing obligations	60	60
Asset retirement obligation	48	55
Trust obligations	47	57
Workers' compensation liability	32	32
Finance lease liability	27	—
Contract deposit	25	22
Other	66	73
Total other long-term liabilities	<u>\$ 2,303</u>	<u>\$ 2,083</u>

## Mayo Clinic

### Notes to Consolidated Financial Statements (In Millions)

---

#### Note 19. Other Revenue

For the years ended December 31, other revenue consisted of the following:

	2023	2022
Retail pharmacy sales	\$ 530	\$ 475
Royalties	120	130
Retail Stores	80	71
Oil and gas producing activities	75	156
Graduate medical and other education revenue	53	46
Technology commercialization, health information, and medical products	43	43
Cafeteria revenue	37	32
Other	262	274
Total other revenue	<u>\$ 1,200</u>	<u>\$ 1,227</u>

#### Note 20. Commitments and Contingencies

The Clinic has various construction projects in progress related to patient care, research, and educational facilities. The estimated costs committed to complete the various projects at December 31, 2023 is \$6,117 all of which is expected to be expended over the next three to five years. Included in this is the \$5 billion initiative for the Rochester, Minnesota campus project which includes five new buildings, and technology and infrastructure investments.

While the Clinic is self-insured for a substantial portion of its general and workers' compensation liabilities, the Clinic maintains commercial insurance coverage against catastrophic loss. Additionally, the Clinic maintains a self-insurance program for its long-term disability coverage. The provision for estimated self-insured claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

The Clinic is a defendant in various lawsuits arising in the ordinary course of business and records an estimated liability for probable claims. Although the outcome of these lawsuits cannot be predicted with certainty, management believes the ultimate disposition of such matters will not have a material effect on the Clinic's consolidated financial position or consolidated statement of activities.

**Mayo Clinic****Notes to Consolidated Financial Statements (In Millions)****Note 21. U.S. Department of Education Financial Responsibility Ratio Information**

The following information is required by the U.S. Department of Education for the years ended December 31,

	2023	2022
Net assets with temporary donor restrictions	\$ 3,221	\$ 2,989
Intangible assets	\$ 10	\$ 1
Post-employment and retirement liabilities:		
Accrued pension and postretirement benefits, net of current portion	\$ 812	\$ 819
Postretirement benefits, current portion	57	56
Total post-employment and retirement liabilities	\$ 869	\$ 875
Property, plant, and equipment, including construction in progress and right-of-use asset, net of accumulated depreciation:		
Property, plant, and equipment, net	\$ 6,431	\$ 5,887
Right-of-use asset	122	141
Total property, plant, and equipment, including construction in progress and right-of-use asset, net of accumulated depreciation	\$ 6,553	\$ 6,028
Long-term debt obtained for long term purposes:		
Long-term debt	\$ 4,736	\$ 4,777
Operating lease liabilities	149	146
Finance lease liabilities	36	6
Total long-term debt obtained for long term purposes	\$ 4,921	\$ 4,929
Expenses and losses without donor restrictions:		
Operating expenses	\$ 16,860	\$ 15,695
Contributions not available for current activities, net	17	22
Income tax expense	41	23
Pension and other postretirement benefit adjustments	648	—
Other	162	—
Unallocated investment loss, net	—	1,382
Total expenses and losses without donor restrictions	\$ 17,728	\$ 17,122
Revenue without donor restrictions:		
Total revenue, gains, and other support	\$ 18,028	\$ 16,336
Unallocated investment return, net	788	—
Benefit credit	344	175
Pension and other postretirement benefit adjustments	—	2,859
Other	—	129
Total revenue without donor restrictions	\$ 19,160	\$ 19,499

The Clinic does not have any material related party transactions to report for 2023 and 2022.

## Supplementary Information



## Mayo Clinic

### Financial Responsibility Supplemental Schedule Required by the U.S. Department of Education Year Ended December 31, 2023 (In Millions)

Ratio Element	Reference to Financial Statements or Notes	2023
<b>Primary Reserve Ratio</b>		
Expendable Net Assets		
Net assets without donor restrictions	Consolidated Statements of Financial Position	\$ 16,240
Net assets with restrictions	Note 21 - U.S. Department of Education	3,221
Term endowments with donor restrictions	Note 12 - Net Assets with Donor Restrictions	1,455
Intangible assets	Note 21 - U.S. Department of Education	10
Property, plant, and equipment, including construction in progress, and right of use asset, net of accumulated depreciation	Note 21 - U.S. Department of Education	6,553
Long-term debt obtained for long term purposes	Note 21 - U.S. Department of Education	4,921
Post-employment and retirement liabilities	Note 21 - U.S. Department of Education	869
Total Expenses and Losses		
Total expenses and losses without donor restrictions	Note 21 - U.S. Department of Education	17,728
<b>Equity Ratio</b>		
Modified Net Assets		
Net assets with and without donor restrictions	Consolidated Statements of Financial Position	21,636
Intangible assets	Note 21 - U.S. Department of Education	10
Modified Assets		
Total assets	Consolidated Statements of Financial Position	31,927
Intangible assets	Note 21 - U.S. Department of Education	10
<b>Net Income Ratio</b>		
Change in net assets without donor restrictions	Consolidated Statements of Activities	1,432
Total revenue without donor restrictions	Note 21 - U.S. Department of Education	19,160

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DEPARTMENT OF DEFENSE									
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	HR0011-24-C-0332				\$3,408	\$5,250,381	RESEARCH AND DEVELOPMENT	\$445,961,340
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2007			\$436,874	\$1,407,912	\$5,250,381	RESEARCH AND DEVELOPMENT	\$445,961,340
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2017			\$275,970	\$2,917,841	\$5,250,381	RESEARCH AND DEVELOPMENT	\$445,961,340
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2019				\$586,072	\$5,250,381	RESEARCH AND DEVELOPMENT	\$445,961,340
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-20-1-2726				\$259	\$5,250,381	RESEARCH AND DEVELOPMENT	\$445,961,340
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-22-C-2019				\$327,627	\$5,250,381	RESEARCH AND DEVELOPMENT	\$445,961,340
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	BMT CTN 1703/1801	National Marrow Donor Program	BMT CTN 1703/1801		\$7,262	\$5,250,381	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0100				\$10,729	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0110				\$5,478	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0234				\$74,489	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0298				\$21,640	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0328				\$36,534	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0488				\$617,505	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0752				\$47,454	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0754				\$26,156	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-1079				\$21,712	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-2-0026				\$86,249	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-0810-01			\$432,481	\$19,518,528	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0115				\$77,855	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0292			\$22,000	\$591,832	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0293				\$291,709	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0265				\$221,171	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0266				\$254,632	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0268				\$348,124	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0269				\$269,804	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0345				\$111,824	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0563				\$788,310	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0564			\$14,900	\$602,546	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0676				\$2,650	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0760			\$336,285	\$500,339	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0021				\$212,698	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0029				\$112,424	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0081				\$29,479	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0534			\$677,409	\$1,854,691	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0583				\$434,444	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0214				\$164,950	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0215				\$103,814	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0262				\$51,473	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0322				\$90,723	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0400				\$416,461	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0514				\$135,720	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0662				\$98,623	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0752				\$208,323	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0886				\$125,522	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0923			\$169,832	\$416,636	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0063				\$149,563	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0182			\$164,822	\$181,205	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0405				\$199,957	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0428				\$294,255	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0475				\$254,798	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0489				\$241,516	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0490			\$75,788	\$1,245,553	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0624				\$338,502	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0678				\$254,558	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0704				\$461,850	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0705				\$64,539	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0706				\$46,742	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0798				\$199,138	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0867				\$195,798	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0888				\$207,294	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-2-0036			\$32,961	\$87,523	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0021				\$7,149	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0245				\$947,093	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0288				\$410,639	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0289				\$156,024	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0313				\$308,365	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0634				\$93,303	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0670				\$22,060	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0917				\$305,399	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0968			\$87,293	\$797,698	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0969				\$37,477	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-23-1-0752				\$3,305	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	APP-304092	Applied Research Associates	APP-304092		\$10,000	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0485	Boston Scientific Corporation	HT9425-23-1-0485		\$43,801	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0681	Targepeutics, Inc.	HT9425-23-1-0681		\$9,468	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-0317	Cedars Sinai Medical Center	W81XWH-0317		\$164,084	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0705	University of Alabama at Birmingham	W81XWH-15-1-0705		\$26,607	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-9-001	University of Pittsburgh	W81XWH-15-9-001		\$356,705	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0644	Massachusetts Eye & Ear Infirmary	W81XWH-17-1-0644		\$1,788	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0073	University of Pittsburgh	W81XWH-17-2-0073		\$7,578	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0577	University of Minnesota	W81XWH-18-1-0577		\$10,160	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0491	MD Anderson Cancer Center	W81XWH-19-1-0491		\$76,859	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0727	University of California Davis	W81XWH-19-1-0727		\$21,288	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0171	Southwest Autism Research & Resource Center	W81XWH-20-1-0171		\$1,402	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0432	University of Maryland	W81XWH-20-1-0432		\$1,507	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0524	Prytime Medical Devices, Inc.	W81XWH-20-1-0524		\$84,188	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0682	University of Minnesota	W81XWH-20-1-0682		\$278,505	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0750	Cleveland Clinic Foundation	W81XWH-20-1-0750		\$68,851	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0930	University of New Mexico	W81XWH-20-1-0930		\$44,688	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-C-0104	Treadmetrix	W81XWH-20-C-0104		\$25,026	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0121	Prytime Medical Devices, Inc.	W81XWH-21-1-0121		\$36,836	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0401	University of Melbourne	W81XWH-21-1-0401		\$103	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0480	University of Pittsburgh Medical Center	W81XWH-21-1-0480		\$278,239	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0665	University of Alabama at Birmingham	W81XWH-21-1-0665		\$233,469	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0726	University of Minnesota	W81XWH-21-1-0726		\$10,821	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0827	Cure HHT Foundation	W81XWH-21-1-0827		\$7,412	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-9-0014	University of Pittsburgh	W81XWH-21-9-0014		\$123,736	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-C-0025	Vivonics, Inc.	W81XWH-21-C-0025		\$141,761	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0201	University of Iowa	W81XWH-22-1-0201		\$21,781	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0971	Georgia College & State University	W81XWH-22-1-0971		\$22,554	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0999	Mount Sinai Medical Center	W81XWH-22-1-0999		\$565	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-3-0001	University of Alabama at Birmingham	W81XWH-22-3-0001		\$239	\$19,518,528	RESEARCH AND DEVELOPMENT	\$445,961,340
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750	HU00011920072	Henry M. Jackson Foundation	HU00011920072		\$176,257	\$176,257	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	140D0422C0053	Luna Innovations Incorporated	140D0422C0053		\$97,769	\$97,769	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	36C26223C0234				\$10,358	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	6973GH-23-T-00009				\$146,333	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	FA8650-19-C-6979			\$96,136	\$1,305,330	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	H98230-13-D-0123				\$173,150	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	H98230-18-D-0024			\$240,000	\$5,104,265	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CONTRACT	12.RD	H98230-22-C-0095			\$56,850	\$1,324,986	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	MTEC 2020-625				\$1,289,676	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	MTEC 2020-625A				\$38,853	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	MTEC 2020-625B			\$578	\$578	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	75D30122C15355	University of Wisconsin-Madison	75D30122C15355		\$4,808	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	75N93019C00052	University of Georgia	75N93019C00052		\$185,541	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	75N93019C00056	Crestone, Inc.	75N93019C00056		\$10,315	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	12.RD	DE-AC05-76RL01830	Battelle Memorial Institute	DE-AC05-76RL01830		\$133,212	\$9,727,405	RESEARCH AND DEVELOPMENT	\$445,961,340
TOTAL DEPARTMENT OF DEFENSE					\$3,120,179	\$34,770,340			
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT									
SUPPORTIVE HOUSING FOR THE ELDERLY	14.157	Supportive Housing For The Elderly				\$302,998	\$302,998	N/A	\$0
SECTION 8 HOUSING CHOICE VOUCHERS	14.871	Section 8 Housing Choice Vouchers				\$81,532	\$81,532	HOUSING VOUCHER CLUSTER	\$81,532
TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT						\$384,530			
DEPARTMENT OF JUSTICE									
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2020-75-CX-0015				\$61,857	\$61,857	RESEARCH AND DEVELOPMENT	\$445,961,340
CRIME VICTIM ASSISTANCE	16.575	Crime Victim Assistance				\$93,603	\$93,603	N/A	\$0
TOTAL DEPARTMENT OF JUSTICE						\$155,460			
DEPARTMENT OF THE TREASURY									
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19				\$74,699	\$781,759	N/A	\$0
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19	University of Wisconsin-Madison	435100-G23		\$76,171	\$781,759	N/A	\$0
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19	Arizona State Board of Nursing	HB2691		\$630,889	\$781,759	N/A	\$0
TOTAL DEPARTMENT OF THE TREASURY						\$781,759			
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
SCIENCE	43.001	80NSSC20K0116				\$19,275	\$209,503	RESEARCH AND DEVELOPMENT	\$445,961,340
SCIENCE	43.001	80NSSC20K1139				\$168	\$209,503	RESEARCH AND DEVELOPMENT	\$445,961,340
SCIENCE	43.001	80NSSC21K0299				\$190,033	\$209,503	RESEARCH AND DEVELOPMENT	\$445,961,340
SCIENCE	43.001	80NSS22K0563	Center for Applied Space Technology, Inc.	80NSS22K0563		\$27	\$209,503	RESEARCH AND DEVELOPMENT	\$445,961,340
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION						\$209,503			
NATIONAL SCIENCE FOUNDATION									
ENGINEERING	47.041	NSF #2152869	Texas A&M University	NSF #2152869		\$108,725	\$193,127	RESEARCH AND DEVELOPMENT	\$445,961,340
ENGINEERING	47.041	NSF #2229279	Arizona State University	NSF #2229279		\$37,496	\$193,127	RESEARCH AND DEVELOPMENT	\$445,961,340
ENGINEERING	47.041	NSF 2127127	Frontier Bio Corporation	NSF 2127127		\$46,018	\$193,127	RESEARCH AND DEVELOPMENT	\$445,961,340
ENGINEERING	47.041	NSF2111884	Sequitur Health Corporation	NSF2111884		\$888	\$193,127	RESEARCH AND DEVELOPMENT	\$445,961,340
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF #10				\$156,312	\$232,451	RESEARCH AND DEVELOPMENT	\$445,961,340
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF 2113360				\$20,131	\$232,451	RESEARCH AND DEVELOPMENT	\$445,961,340
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF #9	Georgia Institute of Technology	NSF #9		\$42,670	\$232,451	RESEARCH AND DEVELOPMENT	\$445,961,340
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF 2108060	University of North Florida	NSF 2108060		\$13,338	\$232,451	RESEARCH AND DEVELOPMENT	\$445,961,340
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1837572				\$48,534	\$837,557	RESEARCH AND DEVELOPMENT	\$445,961,340
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2041339			\$57,850	\$300,610	\$837,557	RESEARCH AND DEVELOPMENT	\$445,961,340
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2123900				\$228,766	\$837,557	RESEARCH AND DEVELOPMENT	\$445,961,340
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF #2200269	Georgia Institute of Technology	NSF #2200269		\$33,549	\$837,557	RESEARCH AND DEVELOPMENT	\$445,961,340
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1901046	Purdue University	NSF 1901046		\$20,803	\$837,557	RESEARCH AND DEVELOPMENT	\$445,961,340
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2002540	University of Illinois at Urbana Champaign	NSF 2002540		\$7,176	\$837,557	RESEARCH AND DEVELOPMENT	\$445,961,340
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2200058	Oxalo Therapeutics, Inc.	NSF 2200058		\$198,119	\$837,557	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BIOLOGICAL SCIENCES	47.074	NSF 23494	Iowa State University	NSF 23494		\$54,543	\$54,543	RESEARCH AND DEVELOPMENT	\$445,961,340
STEM EDUCATION (Formerly EDUCATION AND HUMAN RESOURCES)	47.076	NSF-GRFP21				\$41,946	\$57,601	RESEARCH AND DEVELOPMENT	\$445,961,340
STEM EDUCATION (Formerly EDUCATION AND HUMAN RESOURCES)	47.076	NSF 2152254	Arizona State University	NSF 2152254		\$11,368	\$57,601	RESEARCH AND DEVELOPMENT	\$445,961,340
STEM EDUCATION (Formerly EDUCATION AND HUMAN RESOURCES)	47.076	NSF 2216826	St. Catherine University	NSF 2216826		\$4,287	\$57,601	RESEARCH AND DEVELOPMENT	\$445,961,340
TOTAL NATIONAL SCIENCE FOUNDATION						\$57,850	\$1,375,279		
DEPARTMENT OF VETERANS AFFAIRS									
CONTRACT	64.RD	IPA AGREEMENT - KAUFMAN				\$63,832	\$82,219	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	64.RD	IPA AGREEMENT - WANG				\$18,387	\$82,219	RESEARCH AND DEVELOPMENT	\$445,961,340
TOTAL DEPARTMENT OF VETERANS AFFAIRS							\$82,219		
DEPARTMENT OF EDUCATION									
FEDERAL PELL GRANT PROGRAM	84.063	PELL #1				\$21,084	\$21,084	STUDENT FINANCIAL ASSISTANCE	\$18,084,664
FEDERAL DIRECT STUDENT LOANS	84.268	Federal Direct Student Loans				\$18,063,580	\$18,063,580	STUDENT FINANCIAL ASSISTANCE	\$18,084,664
TOTAL DEPARTMENT OF EDUCATION							\$18,084,664		
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
CHRONIC DISEASES: RESEARCH, CONTROL, AND PREVENTION BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.068	DP06703	Great Lakes Hemophilia Foundation	NU27DD000020		\$752,871	\$752,871	RESEARCH AND DEVELOPMENT	\$445,961,340
PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES	93.080	NU27DD000020	American Society Clinical Oncology	NH23IP922656		\$19,590	\$19,590	RESEARCH AND DEVELOPMENT	\$445,961,340
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.083	NH23IP922656	Minnesota Department of Health	NU50CK000628		\$97,084	\$97,084	RESEARCH AND DEVELOPMENT	\$445,961,340
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	75F40122C00183	University of Missouri - Kansas City	75F40122C00183		\$56,936	\$56,936	RESEARCH AND DEVELOPMENT	\$445,961,340
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	HRSA-22-145	Cure HHT Foundation	HRSA-22-145		\$79,606	\$107,825	RESEARCH AND DEVELOPMENT	\$445,961,340
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MC24052	Great Lakes Hemophilia Foundation	MC24052		\$28,219	\$107,825	RESEARCH AND DEVELOPMENT	\$445,961,340
ENVIRONMENTAL HEALTH	93.113	ES33892	Florida International University	ES33892		\$64,479	\$64,479	RESEARCH AND DEVELOPMENT	\$445,961,340
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE031424			\$147,344	\$259,747	\$324,000	RESEARCH AND DEVELOPMENT	\$445,961,340
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE28105				\$994	\$324,000	RESEARCH AND DEVELOPMENT	\$445,961,340
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE29754	University of North Carolina University of Kansas Medical Center	DE29754		\$63,259	\$324,000	RESEARCH AND DEVELOPMENT	\$445,961,340
GRANTS TO INCREASE ORGAN DONATIONS	93.134	HS33878		HS33878		\$20,030	\$20,030	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG06379			\$224,276	\$1,509,235	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG09542				\$24,956	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG11461			\$249,371	\$434,175	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG11662			\$67,991	\$159,136	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG11710				\$856,190	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG11899				\$421,086	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG06834	Brigham and Women's Hospital	HG06834		\$102,483	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG09650	University of North Carolina Case Western Reserve University	HG09650		\$180,525	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG09668		HG09668		\$55,530	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG10166	Cincinnati Children's Hospital	HG10166		\$58,100	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
HUMAN GENOME RESEARCH	93.172	HG12402	University of North Carolina	HG12402		\$80,488	\$3,881,904	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC019564				\$34,265	\$1,475,716	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC021115			\$5,066	\$7,338	\$1,475,716	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC12519				\$585,844	\$1,475,716	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC14942				\$280,487	\$1,475,716	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC19114			\$2,577	\$436,430	\$1,475,716	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC18920	Ohio State University	DC18920		\$62,866	\$1,475,716	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC19402	Michigan State University	DC19402		\$54,288	\$1,475,716	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC19475	Arizona State University	DC19475		\$14,198	\$1,475,716	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT010875				\$621,463	\$1,469,089	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT12185				\$664,931	\$1,469,089	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT09665	Minnesota HealthSolutions Corporation	AT09665		\$177,103	\$1,469,089	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT09844	New York School of Medicine	AT09844		\$5,592	\$1,469,089	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS028475				\$123,217	\$788,037	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS26609			\$14,058	\$14,058	\$788,037	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS28060				\$17,013	\$788,037	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS28639			\$25,230	\$386,093	\$788,037	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS29774				\$82,737	\$788,037	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS25412	Virginia Commonwealth University	HS25412		\$17,596	\$788,037	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS26379	University of Minnesota	HS26379		\$92,830	\$788,037	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS26622	University of Michigan	HS26622		\$39,281	\$788,037	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS28583	University of Minnesota	HS28583		\$15,212	\$788,037	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL134808				\$680,731	\$2,546,784	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL134885				\$133,101	\$2,546,784	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL146114				\$709,433	\$2,546,784	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL160619				\$613,739	\$2,546,784	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL65176				\$335,672	\$2,546,784	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL160368	REMastered Sleep LLC	HL160368		\$13,830	\$2,546,784	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL162131	Minnesota HealthSolutions Corporation	HL162131		\$28,199	\$2,546,784	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL168173	Binghamton University	HL168173		\$32,079	\$2,546,784	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121924				\$276,660	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH122258			\$111,326	\$315,081	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH124655			\$74,361	\$644,107	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH128296				\$66,184	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH131623				\$18,212	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH131254				\$48,059	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH109190	Minnesota HealthSolutions Corporation	MH109190		\$60,929	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH114967	Research Foundation for Mental Hygiene, Inc.	MH114967		\$15,620	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121191	Harvard School of Public Health	MH121191		\$146,136	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH125935	University of Washington	MH125935		\$98,498	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH126700	University of California San Diego	MH126700		\$47,767	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH129278	Advanced MRI Technologies, LLC	MH129278		\$17,235	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
MENTAL HEALTH RESEARCH GRANTS	93.242	MH129301	Yale University	MH129301		\$161,880	\$1,916,368	RESEARCH AND DEVELOPMENT	\$445,961,340
IMMUNIZATION COOPERATIVE AGREEMENTS	93.268	MDH203179	Minnesota Department of Health	MDH203179		\$447,310	\$561,959	RESEARCH AND DEVELOPMENT	\$445,961,340
IMMUNIZATION COOPERATIVE AGREEMENTS	93.268	MDH220856	Minnesota Department of Health	MDH220856		\$114,649	\$561,959	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA21171				\$533,049	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA21788				\$261,161	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA26886				\$20,745	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA26887				\$315,907	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA26974				\$249,386	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA27179			\$117,383	\$294,921	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA27486				\$234,262	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA27487			\$702,905	\$702,905	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA28050				\$133,211	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALCOHOL RESEARCH PROGRAMS	93.273	AA28968				\$121,769	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA29258				\$381,348	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA30273				\$103,070	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA30587				\$31,299	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
ALCOHOL RESEARCH PROGRAMS	93.273	AA20735	University of Nebraska	AA20735		\$280,983	\$3,664,016	RESEARCH AND DEVELOPMENT	\$445,961,340
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	CA278594			\$5,939	\$909,569	\$2,343,095	RESEARCH AND DEVELOPMENT	\$445,961,340
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA42492				\$213,555	\$2,343,095	RESEARCH AND DEVELOPMENT	\$445,961,340
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA55848				\$88,088	\$2,343,095	RESEARCH AND DEVELOPMENT	\$445,961,340
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA56469			\$258,738	\$490,643	\$2,343,095	RESEARCH AND DEVELOPMENT	\$445,961,340
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA57928				\$117,485	\$2,343,095	RESEARCH AND DEVELOPMENT	\$445,961,340
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	NS1133515				\$161,254	\$2,343,095	RESEARCH AND DEVELOPMENT	\$445,961,340
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	CA261067	NYU Langone Medical Center	CA261067		\$78,926	\$2,343,095	RESEARCH AND DEVELOPMENT	\$445,961,340
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA40316	Hennepin Healthcare Research	DA40316		\$129,790	\$2,343,095	RESEARCH AND DEVELOPMENT	\$445,961,340
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA47003	Yale University	DA47003		\$123,916	\$2,343,095	RESEARCH AND DEVELOPMENT	\$445,961,340
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA54725	Washington University	DA54725		\$29,869	\$2,343,095	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB001981				\$509,083	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17095				\$179,510	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17197				\$471,658	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB19403			\$156,532	\$503,495	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB24450			\$100,741	\$334,108	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26780			\$7,497	\$102,810	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27064				\$81,109	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28590				\$552,345	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28591				\$198,703	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28936				\$250,802	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB30529			\$138,180	\$481,168	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB31790				\$718,678	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB33008				\$304,590	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17270	The Research Foundation for SUNY	EB17270		\$1,121	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26284	University of Southern California	EB26284		\$162	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26976	GE Capital	EB26976		\$26,002	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27100	Stanford University	EB27100		\$27,169	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB29242	Montana State University	EB29242		\$69,031	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB31040	University Illinois-Urbana Champaign	EB31040		\$31,737	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB31992	Massachusetts Institute of Technology	EB31992		\$84,597	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB32958	University of Southern California	EB32958		\$9,325	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB35403	Arizona State University	EB35403		\$4,164	\$4,941,367	RESEARCH AND DEVELOPMENT	\$445,961,340
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD16230				\$156,277	\$1,505,518	RESEARCH AND DEVELOPMENT	\$445,961,340
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD17217				\$143,087	\$1,505,518	RESEARCH AND DEVELOPMENT	\$445,961,340
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD007582	Florida A&M University	MD007582		\$34,938	\$1,505,518	RESEARCH AND DEVELOPMENT	\$445,961,340
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD012388	Northern Arizona University	MD012388		\$31,298	\$1,505,518	RESEARCH AND DEVELOPMENT	\$445,961,340
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD17342	University of Minnesota	MD17342		\$1,099,649	\$1,505,518	RESEARCH AND DEVELOPMENT	\$445,961,340
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD17690	Moorhouse School of Medicine	MD17690		\$40,269	\$1,505,518	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	A1142773				\$287,321	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	CA220378				\$67,657	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	CA268103				\$786,695	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	CA272883				\$275,944	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	DK112326				\$1,071,621	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	OD023121				\$24,072,734	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	OD034496				\$80,063	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	OD23121				\$9,189,180	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	TRO2471				\$244,488	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	AG75941	University of Connecticut	AG75941		\$153,903	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	AG79754	University of Minnesota	AG79754		\$281,707	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	AG79758	Sanford-Burnham Medical	AG79758		\$20,034	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	AG79779	Johns Hopkins University	AG79779		\$290,524	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	CA268091	University of Michigan	CA268091		\$14,272	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	GM118971	University of Texas at El Paso	GM118971		\$2,644	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	NS122602	Conway Medical, LLC	NS122602		\$22,474	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANS-NIH RESEARCH SUPPORT	93.310	OD32701	Massachusetts General Hospital	OD32701		\$57,772	\$36,919,033	RESEARCH AND DEVELOPMENT	\$445,961,340
PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	93.318	NU3HCK000006	Vanderbilt University Medical Center	NU3HCK000006		\$52,355	\$52,355	RESEARCH AND DEVELOPMENT	\$445,961,340
EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES (ELC)	93.323	NU50CK00058	Minnesota Department of Health	NU50CK00058		\$37,947	\$37,947	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TRO02377			\$20,205	\$7,461,664	\$10,024,071	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TRO02379				\$1,081,256	\$10,024,071	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TRO2062				\$121,157	\$121,157	RESEARCH AND DEVELOPMENT	\$445,961,340



MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TRO2380				\$526,297	\$10,024,071	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TRO2743			\$378,778	\$833,697	\$10,024,071	RESEARCH AND DEVELOPMENT	\$445,961,340
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD20166	Iowa State University	OD20166		\$210,619	\$210,619	RESEARCH AND DEVELOPMENT	\$445,961,340
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA224018			\$27,503	\$277,385	\$2,293,175	RESEARCH AND DEVELOPMENT	\$445,961,340
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA233033			\$59,815	\$940,416	\$2,293,175	RESEARCH AND DEVELOPMENT	\$445,961,340
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA246568			\$59,419	\$706,130	\$2,293,175	RESEARCH AND DEVELOPMENT	\$445,961,340
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA233046	University of North Carolina	CA233046		\$369,070	\$2,293,175	RESEARCH AND DEVELOPMENT	\$445,961,340
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA252973	University of New Mexico	CA252973		\$174	\$2,293,175	RESEARCH AND DEVELOPMENT	\$445,961,340
PUBLIC HEALTH EMERGENCY RESPONSE: COOPERATIVE AGREEMENT			Minnesota Department of Health						
FOR EMERGENCY RESPONSE: PUBLIC HEALTH CRISIS RESPONSE	93.354	NU90TP92		NU90TP92		\$11,769	\$11,769	RESEARCH AND DEVELOPMENT	\$445,961,340
NURSING RESEARCH	93.361	NR020362				\$193,393	\$1,367,570	RESEARCH AND DEVELOPMENT	\$445,961,340
NURSING RESEARCH	93.361	NR16433			\$7,596	\$242,450	\$1,367,570	RESEARCH AND DEVELOPMENT	\$445,961,340
NURSING RESEARCH	93.361	NR18832				\$696,846	\$1,367,570	RESEARCH AND DEVELOPMENT	\$445,961,340
NURSING RESEARCH	93.361	NR20362			\$20,300	\$234,881	\$1,367,570	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA195568			\$1,521,258	\$2,938,008	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA207084				\$70,874	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217889				\$493,664	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA224917			\$37,252	\$275,741	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225662			\$180,000	\$710,202	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA230712				\$655,958	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233610			\$133,845	\$732,782	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233700				\$292,756	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA234943				\$95,735	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA235026				\$509,796	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237398			\$18,188	\$516,163	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237607			\$134,720	\$1,054,663	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA248288			\$218,981	\$562,182	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA253187				\$672,553	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA254951				\$719,284	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA258058			\$102,402	\$143,335	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA259201			\$18,288	\$1,043,210	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA262393			\$1,966	\$431,430	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA264600				\$431,245	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA265018				\$30,000	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA265050				\$617,777	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA269264			\$144,169	\$309,557	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA271014			\$202,278	\$799,560	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA271503				\$247,059	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA272473				\$383,734	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA272668				\$3,447	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA272883				\$39,546	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA275065				\$307,462	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA275074			\$65,441	\$195,671	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA277825				\$444,144	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA167551	Stanford University	CA167551		\$214,636	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA207369	University of Massachusetts	CA207369		\$17,723	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA224293	University of Virginia	CA224293		\$76,744	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233432	Kaiser Foundation Research Institute	CA233432		\$37,400	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA243483	Baylor College of Medicine	CA243483		\$57,604	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA244670	University of Washington	CA244670		\$95,608	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA246510	St. Jude Children's Hospital	CA246510		\$90,100	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA247283	Johns Hopkins University	CA247283		\$5,047	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA247642	Alaska Native Tribal Health Consortium	CA247642		\$6,894	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA255082	University of Washington	CA255082		\$28,047	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA256810	Washington University	CA256810		\$50,711	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA258119	University of Vermont	CA258119		\$11,660	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA26211	University of Wisconsin Madison	CA26211		\$34,780	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA262265	Tufts Medical Center, Inc.	CA262265		\$80,871	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA265967	University of Texas Southwestern Medical Center	CA265967		\$55,385	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA269617	NYU Grossman School of Medicine	CA269617		\$79,397	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA269832	Ohio State University	CA269832		\$18,338	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CAUSE AND PREVENTION RESEARCH	93.393	HD100540	Johns Hopkins University	HD100540		\$18,827	\$16,707,310	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA168762				\$406,193	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA195527				\$140,413	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA206584				\$338,736	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA210138			\$275,616	\$617,198	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA212162				\$68,484	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214679				\$447,170	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA216855			\$27,002	\$42,112	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA217847				\$60,278	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA229811			\$35,382	\$414,622	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA236612				\$32,796	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA237602			\$129,653	\$539,561	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA238926				\$286,025	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239164				\$527,801	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239200			\$172,627	\$519,174	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239548				\$457,948	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA241020				\$15,101	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA241164			\$44,638	\$426,709	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA244167				\$128,330	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251065				\$306,924	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251801			\$227,975	\$599,177	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251923				\$47,938	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA256648			\$23,082	\$92,821	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA257558			\$152,885	\$673,773	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA258465			\$250,128	\$1,190,359	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA260259				\$598,446	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA271410			\$119,906	\$1,325,204	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA272628				\$353,044	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA274496				\$412,116	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA161749	University of Pennsylvania	CA161749		\$7,020	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA186709	Dana-Farber Cancer Institute	CA186709		\$36,721	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA196171	Washington University	CA196171		\$436,728	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214114	Fred Hutchinson Cancer Research Center	CA214114		\$6,165	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA218429	Albert Einstein College of Medicine of Yeshiva University	CA218429		\$174	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA223481	University of Wisconsin Madison	CA223481		\$33,139	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA237659	University of Texas Southwestern Medical Center	CA237659		\$37,349	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA240181	Purdue University	CA240181		\$1,107	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA246704	University of Central Florida	CA246704		\$17,194	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA247606	St. Joseph Hospital	CA247606		\$20,892	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA256969	Regents of the University of California San Francisco	CA256969		\$344,767	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA265879	Rhode Island Hospital	CA265879		\$20,455	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA265945	University of Minnesota	CA265945		\$16,744	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA268452	Rush River Research Corp.	CA268452		\$27,935	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA271402	Washington University	CA271402		\$52,086	\$12,126,929	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA150190				\$166,411	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA180882			\$512,912	\$8,550,918	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA207183			\$96	\$206,593	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA207240				\$46,989	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA207386				\$10,674	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA219960				\$380,316	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	CA225996				\$321,515	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA227954			\$18,864	\$153,446	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA229100			\$927,832	\$1,386,857	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA229560				\$374,931	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA232760				\$978,924	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA248064				\$388,470	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA248147			\$17,477	\$813,866	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA256927				\$394,395	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA258239				\$346,870	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA259236				\$125,421	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA261854				\$603,148	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA262613				\$181,510	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA262994				\$296,277	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA263003				\$99,078	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA264362			\$615,380	\$1,266,501	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA266344				\$730,006	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA266999				\$135,255	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA267098				\$78,085	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA269384				\$213,461	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA270380				\$34,522	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA271431				\$4,933	\$332,465	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA272257			\$147,675	\$414,012	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA272426				\$97,824	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA272496				\$239,994	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA274985				\$734,245	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA275870				\$500,433	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA276005				\$377,392	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA276313				\$305,701	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA276851				\$319,109	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA283479				\$16,586	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA232760	JAEB Center for Health Research, Inc.	CA232760	\$29,194	\$179,923	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	75A50122C00039	GRIP Molecular Technologies	75A50122C00039		\$9,479	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	75N91021C00012	Westat	75N91021C00012		\$38,144	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	AHOD2131	Mayo Clinic Rochester	AHOD2131		\$1,549	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	ASCT2031	Public Health Institute	ASCT2031		\$2,905	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA108671	Mount Sinai Medical Center of Florida	CA108671		\$396,745	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA180820	Coalition of Ntl Cancer Coop	CA180820		\$92,887	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA180821	Brigham and Women's Hospital	CA180821		\$371,579	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA180868	NRG Oncology Foundation, Inc.	CA180868		\$4,905	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA180886	The Children's Hospital Of Philadelphia	CA180886		\$33,315	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA180888	Oregon Health Sciences University	CA180888		\$12,998	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA181255	University of California—San Francisco	CA181255		\$462,140	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA186686	National Cancer Institute	CA186686		\$2,230	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA186709	Dana-Farber Cancer Institute	CA186709		\$1,014,395	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA203430	PPD Development	CA203430		\$3,203	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA205406	Dana-Farber Cancer Institute	CA205406		\$16,739	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA208851	Cedars Sinai Medical Center	CA208851		\$27,997	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA214523	University of Illinois at Urbana Champaign	CA214523		\$16,944	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA217591	Syntrix Biosystems, Inc.	CA217591		\$82,730	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER TREATMENT RESEARCH	93.395	CA227092	Fred Hutchinson Cancer Research Center	CA227092		\$40,746	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
CANCER TREATMENT RESEARCH	93.395	CA228823	The Children's Hospital Of Philadelphia	CA228823		\$43,455	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA233024	Vyriad	CA233024		\$11,147	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA233332	Sloan-Kettering Cancer Research	CA233332		\$61,148	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA233878	Northwestern University	CA233878		\$81,989	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA238946	Ohio State University	CA238946		\$22,368	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA243078	Translational Genomics Research Institute	CA243078		\$59,284	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA248019	University of Minnesota	CA248019		\$22,891	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA249929	University of Pennsylvania	CA249929		\$50,213	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA251910	Sanford-Burnham Medical	CA251910		\$238,619	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA25224	National Cancer Institute University of Louisiana at Monroe	CA25224		\$8,283	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA255176	Monroe	CA255176		\$46,196	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA267372	Iowa State University	CA267372		\$18,411	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA268286	Oleolive, LLC	CA268286		\$200,170	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA272064	Modulation Therapeutics	CA272064		\$28,659	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA275560	Targeptics	CA275560		\$48,206	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA277853	Emmyon, Inc.	CA277853		\$30,773	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA278184	Trekka Therapeutics LLC	CA278184		\$34,589	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CA278293	Myosin Therapeutics	CA278293		\$171,466	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	CALGB 140503	Duke Clinical Research Institute	CALGB 140503		\$627	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER TREATMENT RESEARCH	93.395	NSABP B-47	Mayo Clinic Rochester	NSABP B-47		\$81	\$25,612,328	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA130908				\$44,352	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA203849				\$240,610	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA217833				\$134,760	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA224921				\$463,045	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA225680				\$314,642	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA233790				\$572,437	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA234181				\$394,488	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA239726				\$410,226	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA240323				\$355,980	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA242023				\$278,351	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA243545				\$410,241	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA247929				\$416,943	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA248298				\$147,893	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA249116				\$444,941	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA250481				\$379,458	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA254961				\$347,830	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA255068				\$218,058	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA258274				\$157,124	\$368,029	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER BIOLOGY RESEARCH	93.396	CA261925				\$195,346	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA261932				\$411,256	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA264048				\$81,315	\$559,183	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER BIOLOGY RESEARCH	93.396	CA266113				\$66,479	\$170,656	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER BIOLOGY RESEARCH	93.396	CA269295				\$52,074	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA271486				\$84,561	\$284,710	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER BIOLOGY RESEARCH	93.396	CA272602				\$62,793	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA275669				\$526,165	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA276047				\$62,593	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA81436				\$252,815	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA96985				\$267,933	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA194215	University of Texas Health Science Center	CA194215		\$28,120	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA238720	Technology	CA238720		\$113,403	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA241123	University at Buffalo	CA241123		\$57,931	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA248019	University of Minnesota	CA248019		-\$2,228	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA251443	University of South Wales	CA251443		\$59,357	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA254849	University of Minnesota	CA254849		\$23,722	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA256481	University of Illinois at Urbana Champaign	CA256481		\$57,145	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	
CANCER BIOLOGY RESEARCH	93.396	CA262262	University of Utah	CA262262		\$44,278	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340	

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER BIOLOGY RESEARCH	93.396	CA265892	Joan & Sanford I. Weill Medical College	CA265892		\$17,740	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER BIOLOGY RESEARCH	93.396	CA279065	H. Lee Moffitt Cancer Center & Research Institute	CA279065		\$11,790	\$9,590,211	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CENTERS SUPPORT GRANTS	93.397	CA116201			\$282,293	\$2,248,503	\$14,690,842	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CENTERS SUPPORT GRANTS	93.397	CA136393			\$407,692	\$1,916,735	\$14,690,842	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CENTERS SUPPORT GRANTS	93.397	CA15083			\$124	\$5,534,329	\$14,690,842	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CENTERS SUPPORT GRANTS	93.397	CA186781			\$117,704	\$2,577,336	\$14,690,842	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CENTERS SUPPORT GRANTS	93.397	CA210964			\$468,130	\$1,810,589	\$14,690,842	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CENTERS SUPPORT GRANTS	93.397	CA274504				\$140,716	\$14,690,842	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CENTERS SUPPORT GRANTS	93.397	CA233444	University of Florida	CA233444		\$33,910	\$14,690,842	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CENTERS SUPPORT GRANTS	93.397	CA272170	University of Michigan	CA272170		\$56,296	\$14,690,842	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CENTERS SUPPORT GRANTS	93.397	CA97274	University of Iowa	CA97274	\$780	\$372,428	\$14,690,842	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA257228				\$45,666	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA271560				\$52,899	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA250122				\$32,069	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA214225				\$18,977	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA217836				\$122,163	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA230193				\$185,061	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA236874				\$215,474	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA237875				\$154,224	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA252044				\$74,509	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA273304				\$158,678	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA284259				\$10,179	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA90628				\$706,913	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA235848				\$37,281	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA250326				\$22,957	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER RESEARCH MANPOWER	93.398	CA248972	University of Florida	CA248972		\$9,540	\$1,846,590	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CONTROL	93.399	CA220242				\$165,062	\$1,957,839	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CONTROL	93.399	CA163060	Case Western Reserve University	CA163060		\$13,443	\$1,957,839	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CONTROL	93.399	CA189823	Ohio State University	CA189823		\$1,712,081	\$1,957,839	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CONTROL	93.399	CA189955	The Children's Hospital Of Philadelphia	CA189955		\$4,082	\$1,957,839	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CONTROL	93.399	CA242635	University of Wisconsin Madison	CA242635		\$24,953	\$1,957,839	RESEARCH AND DEVELOPMENT	\$445,961,340
CANCER CONTROL	93.399	CA242643	Northwestern University	CA242643		\$38,218	\$1,957,839	RESEARCH AND DEVELOPMENT	\$445,961,340
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0031				\$506,050	\$632,032	RESEARCH AND DEVELOPMENT	\$445,961,340
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPHF0006	Indiana University	90DPHF0006		\$6,815	\$632,032	RESEARCH AND DEVELOPMENT	\$445,961,340
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0017	Craig Hospital	90DPTB0017		\$10,769	\$632,032	RESEARCH AND DEVELOPMENT	\$445,961,340
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90SIMS0008	University of Minnesota	90SIMS0008		\$108,398	\$632,032	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL07111				\$485,646	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL107304			\$16,589	\$636,228	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117823			\$38,122	\$38,122	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117913				\$700,411	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL119795				\$67,043	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL133501			\$408,882	\$508,817	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134664				\$86,378	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134864				\$219,144	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135879				\$47,493	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136340				\$159,497	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136348				\$215,809	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136440				\$373,982	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL137010				\$45,653	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140951				\$180,013	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142068				\$311,249	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142627				\$213,233	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL144529			\$117,388	\$496,265	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145121				\$230,961	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145268			\$216,584	\$625,826	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL147155				\$205,838	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148144				\$195,032	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148339				\$412,879	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL150086				\$464,443	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL151379				\$351,658	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL153098				\$641,686	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155040				\$51,531	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155506				\$210,090	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL156855			\$58,435	\$518,237	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158517				\$637,476	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158548			\$259,354	\$476,254	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158691			\$103,588	\$503,107	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158932				\$524,958	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160226				\$341,024	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160643				\$319,772	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160761				\$422,992	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161169				\$417,217	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161272				\$75,758	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161821				\$453,933	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL162747			\$107,196	\$426,245	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL162828				\$131,871	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL162830				\$13,436	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164416				\$34,623	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164520				\$572,952	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL165176			\$166,851	\$522,149	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL166204				\$79,704	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL169268				\$114,650	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL81753			\$9,796	\$548,850	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL84155				\$329,847	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL92621				\$90,542	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL98967				\$833,542	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134905	University of Pennsylvania	HL134905		\$7,659	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146127	University of Chicago	HL146127		\$18,945	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146619	University of Michigan	HL146619		\$55,485	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
			University of Illinois at Urbana						
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148664	Champaign	HL148664		\$174,449	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL151079	Northwestern University	HL151079		\$35,258	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL153847	University of Pittsburgh	HL153847		\$6,927	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155373	North Carolina State University	HL155373		\$51,910	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155834	University of Michigan	HL155834		\$56,639	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
			NYU Grossman School of						
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL157220	Medicine	HL157220		\$22,338	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL159216	Indiana University	HL159216		\$14,297	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
			Beth Israel Deaconess Medical						
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161697	Center	HL161697		\$1,600	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161765	Binghamton University	HL161765		\$44,028	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164140	Vivita Technologies, Inc.	HL164140		\$36,310	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
			Cleveland Clinic Foundation						
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164379		HL164379		\$3,021	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
			Massachusetts Institute of						
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL167947	Technology	HL167947		\$9,247	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL96812	Johns Hopkins University	HL96812		\$126,119	\$17,228,298	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL126667			\$49,347	\$383,428	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL130881			\$6,590	\$266,349	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL138150				\$262,067	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL140486			\$30,133	\$541,741	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL142061				\$350,661	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL142933			\$68,262	\$279,543	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL142992			\$302,171	\$471,130	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL146114				\$93,581	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL146741				\$190,500	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL151671				\$149,354	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL152967			\$305,027	\$604,918	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL153026				\$153,457	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	HL153407				\$390,431	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL157984				\$621,685	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL158532			\$274,296	\$647,173	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL158549				\$129,771	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL158811				\$272,615	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL160545				\$234,844	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL160570			\$98,459	\$683,757	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL161674				\$5,044	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL164901				\$129,248	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL166187				\$561,125	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL167732				\$43,429	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL168212				\$80,960	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL169382				\$11,335	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL56470			\$270,143	\$829,399	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL62150				\$390,786	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL88029				\$459,973	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL92961			\$82,500	\$756,101	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL158287	The University of Arizona	HL158287		\$44,282	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL108800	Vanderbilt University Medical Center	HL108800		\$546	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL125177	Cleveland Clinic Foundation	HL125177		\$10,721	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL138998	University of North Carolina	HL138998		\$131,801	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL139054	University of Arizona	HL139054		\$38,882	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL139126	Indiana University	HL139126		\$24,137	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL140177	Massachusetts General Hospital	HL140177		\$37,659	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL141722	Stanford University	HL141722		\$352,732	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL142093	Brigham and Women's Hospital	HL142093		\$18,246	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL142269	University of Pennsylvania	HL142269		\$111,001	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL142596	Boston University	HL142596		\$17,164	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL145265	University of Michigan	HL145265		\$18,654	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL146705	North Dakota State University	HL146705		\$65,354	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL147261	University of Michigan	HL147261		\$3,174	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL148437	National Jewish Health	HL148437		\$14,814	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL151865	University of Colorado	HL151865		\$19,424	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL155410	Stanford University	HL155410		\$156,038	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL156812	Duke University	HL156812		\$554,607	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL157424	National Jewish Health	HL157424		\$224,388	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL158287	The University of Arizona	HL158287		\$163,249	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL158507	Indiana University	HL158507		\$2,792	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL161674	Cleveland Clinic Foundation	HL161674		\$3,763	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL161847	NYU Grossman School of Medicine	HL161847		\$8,751,531	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL162169	Shape Medical Systems, Inc.	HL162169		\$8,763	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL165960	Quench Medical, Inc.	HL165960		\$19,055	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL166402	University of Maryland	HL166402		\$147,167	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
LUNG DISEASES RESEARCH	93.838	HL170961	University of Virginia	HL170961		\$29,642	\$20,576,829	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL137193				\$26,060	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL139854				\$833,186	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL141112				\$377,950	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL146508				\$497,042	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL147852				\$213,826	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL153310				\$175,423	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL159561			\$151,930	\$252,210	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL162729				\$69,395	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL166238			\$56,391	\$107,271	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL167354				\$85,692	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL157401	University of Alabama at Birmingham	HL157401		\$7,834	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
 Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	BMT CTN 1506	National Marrow Donor Program	BMT CTN 1506		\$15,396	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL130724	Versiti	HL130724		\$34,698	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL138325	Washington University in St. Louis	HL138325		\$5,760	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL138645	University of Alabama	HL138645		\$14,138	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL140097	Cleveland Clinic Foundation	HL140097		\$11,674	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL142389	Syntrix Biosystems, Inc.	HL142389		\$20,517	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL147894	University of Washington	HL147894		\$12,353	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL148120	Versiti	HL148120		\$8,108	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL154385	University of Washington	HL154385		\$74,316	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL157401	University of Alabama at Birmingham	HL157401		\$1,567	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL161804	Sanford-Burnham Medical	HL161804		\$257,935	\$3,102,351	RESEARCH AND DEVELOPMENT	\$445,961,340
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	HL151662			\$305,194	\$596,879	\$596,879	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR82227				\$20,843	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR056950				\$440,156	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR077538			\$185,637	\$514,539	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR078552				\$332,756	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR42527				\$221,031	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR46849				\$380,199	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR49069				\$91,565	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR55563			\$515,457	\$640,117	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56212				\$212,497	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56647				\$63,462	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR71762				\$6,140	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR72597				\$207,957	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73147			\$34,530	\$228,100	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73811				\$410,661	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74395			\$288,767	\$694,594	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75037				\$204,190	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75370				\$13,219	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76028				\$104,456	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76312			\$152,091	\$391,704	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76339				\$610,307	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76347				\$657,754	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR77518				\$452,362	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78254				\$143,296	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR79098			\$119,986	\$194,460	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR80745				\$46,907	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81318				\$72,167	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81898				\$19,714	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR82134				\$184,956	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR79842				\$1,101	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR55557	Brigham and Women's Hospital	AR55557		\$21,546	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR69400	Emmyon, Inc.	AR69400		\$188,025	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76568	University of Pittsburgh	AR76568		\$107,261	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR77360	Johns Hopkins University	AR77360		\$15,292	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78073	University of Michigan	AR78073		\$26,534	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78389	University of California Irvine	AR78389		\$34,979	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78924	Rhode Island Hospital	AR78924		\$90,204	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81040	Northeastern University	AR81040		\$78,778	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81382	University of Texas Health at Houston	AR81382		\$3,379	\$8,127,208	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124190				\$5,000	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127564				\$46,810	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128913				\$21,883	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124190				\$4,520	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124190				\$88,661	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07013				\$214,810	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07198				\$457,398	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07352				\$469,290	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK078646			\$59,727	\$436,053	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101405				\$169,879	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340



MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101405				\$169,879	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107255				\$24,461	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288				\$421,218	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109134				\$5,813	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110136				\$29,770	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111378				\$516,842	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113999			\$41,055	\$195,511	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114007				\$614,391	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114460				\$104,133	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115575			\$127,919	\$186,053	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116231				\$521,207	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117212			\$19,444	\$27,327	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117861				\$309,123	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117910				\$385,680	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118120				\$92,822	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118391				\$32,215	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118619			\$560,548	\$1,136,898	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119167				\$30,263	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120292				\$371,968	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120559				\$121,394	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121204				\$238,064	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121766				\$375,299	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121888				\$73,765	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121943				\$68,977	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122280				\$55,416	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122734				\$369,760	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122948				\$430,845	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123138				\$176,439	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123549				\$238,782	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124182				\$284,458	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124358				\$137,584	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125252			\$11,729	\$578,716	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125680				\$144,797	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126206			\$42,583	\$298,688	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126662				\$407,803	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126691			\$274,920	\$972,515	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126827				\$510,797	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127010				\$39,375	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127978				\$398,950	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127992				\$435,897	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127998				\$326,450	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128017				\$398,493	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128127				\$25,075	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128552				\$439,232	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128844				\$571,824	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129205				\$226,951	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129208				\$141,695	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129240			\$16,598	\$415,827	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129241				\$377,549	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129297				\$344,951	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129315			\$248,489	\$807,479	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129708				\$261,429	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129886				\$98,265	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129897				\$278,518	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130181				\$380,408	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130331				\$466,208	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130566				\$598,598	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130854				\$314,971	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130884				\$358,426	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131455				\$549,025	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131685				\$378,731	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131946				\$202,118	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132121				\$200,991	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132651				\$401,686	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132718				\$123,047	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133171				\$676,077	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133194				\$356,210	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133401				\$500,036	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133643				\$53,807	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133897				\$55,075	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134366				\$128,625	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134661				\$78,364	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134759				\$156,770	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134765				\$53,760	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134767				\$27,094	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135097				\$330,001	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135200				\$20,098	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135407				\$86,674	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135440				\$69,272	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136181				\$19,257	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136511				\$121,929	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136731				\$46,857	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136906				\$42,108	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138818				\$17,807	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK24031				\$36,492	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK40484				\$417,343	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK44650				\$87,235	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK45343				\$541,250	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK52766				\$420,002	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57061				\$137,869	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57993				\$376,448	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK58816				\$443,275	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59597				\$613,306	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59615				\$295,904	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK78924				\$394,231	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84567				\$1,182,954	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK90358			\$54,095	\$692,319	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92255				\$279,765	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92460				\$444,558	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK98468				\$440,787	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK99160				\$144,691	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124190				\$92,780	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	APOL1	University of Miami	APOL1		\$396	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100846	University of Pennsylvania The Research Institute at	DK100846		\$2,018	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100866	Nationwide Children's Hospital	DK100866		\$1,933	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101240	Oasis Pharmaceuticals, LLC	DK101240		\$183,904	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104833	Medical University of South Carolina	DK104833		\$13,127	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106993	University of South Florida	DK106993		\$13,320	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107733	University of Texas Southwestern Medical Center	DK107733		\$257,164	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288	University of Texas Washington University in St. Louis	DK108288		\$56,208	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110986	Children's Hospital of Philadelphia	DK110986		\$151,408	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114786	Northwestern University	DK114786		\$1,666	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114857	Georgia Regents University	DK114857		\$8,370	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115255	University of North Carolina	DK115255		\$12,809	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115575	University of Wisconsin- Madison	DK115575		\$227,845	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116092	Joslin Diabetes Center	DK116092		\$14,473	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116102	Medical University of South Carolina	DK116102		\$12,716	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116743	Sanford-Burnham Medical Massachusetts General Hospital	DK116743		\$5,972	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117133	Harvard University Jaeb Center for Health Research	DK117133		\$196,701	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117236		DK117236		\$838	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120261		DK120261		\$121,385	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120358		DK120358		\$23,914	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121240		DK121240		\$17	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121330	University of Texas Houston Jaeb Center for Health Research	DK121330		\$29,023	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122603		DK122603		\$161,098	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123441	Arizona State University	DK123441		\$48,557	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125243	Adva-Tec, Ins.	DK125243		\$70,562	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125431	University of Minnesota	DK125431		\$367,449	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125495	Cedars Sinai Medical Center	DK125495		\$111,007	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125680	Johns Hopkins University	DK125680		-\$2,765	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125692	University of Alabama	DK125692		\$18,445	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125911	Duke University	DK125911		\$10,130	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126110	University of Maryland- Baltimore	DK126110		\$155,878	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127157	University of North Carolina	DK127157		\$5,086	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127403	Cedars Sinai Medical Center	DK127403		\$10,392	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128100	University of Pittsburgh	DK128100		\$163,438	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128842	University of Colorado	DK128842		\$42,346	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129191	University of Colorado	DK129191		\$33,001	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129259	University of Colorado	DK129259		\$27,616	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129564	Virginia Commonwealth University	DK129564		\$46,154	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129616	Yale University	DK129616		\$51,125	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131133	University of Illinois at Urbana Champaign	DK131133		\$22,764	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131586	University of Pittsburgh	DK131586		\$123,668	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131708	Maggie's Pearl, LLC.	DK131708		\$60,766	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132001	University of North Carolina	DK132001		\$17,573	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132709	Indiana University	DK132709		\$8,852	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132781	University of Minnesota	DK132781		\$1,472	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133947	University of Chicago	DK133947		\$432,199	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134321	Northwestern University	DK134321		\$2,908	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134482	Hennepin Healthcare Research Institute	DK134482		\$60,423	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK29953	University of Virginia	DK29953		\$31,212	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57846	Yale University	DK57846		\$10,657	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK74008	Johns Hopkins University	DK74008		\$358,181	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK83912	University of Michigan	DK83912		\$14,473	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84567	Case Western Reserve University	DK84567		\$43,200	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK88925	University of Wisconsin Madison	DK88925		\$3,505	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK94157	Case Western Reserve University	DK94157		\$82,830	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	MAYO-UOFM #203	University of Minnesota	MAYO-UOFM #203		\$156,484	\$35,933,190	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115202				\$33,555	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129252				\$23,445	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS085070				\$740,771	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS092882				\$280,216	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100620				\$2,330,487	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS101721				\$214,951	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS102360				\$86,521	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103212				\$393,869	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103870			\$486,237	\$704,204	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS105853				\$112,550	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107336				\$50,300	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107946				\$100,371	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS109491				\$146,457	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110085				\$348,466	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110435			\$1,170,665	\$1,993,987	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110930				\$221,460	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110949				\$393,651	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112144			\$9,750	\$815,733	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112153				\$437,347	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112176			\$5,594	\$29,853	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112339				\$231,264	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113315			\$113,618	\$379,216	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113760				\$369,110	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113776				\$295,307	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113803				\$618,648	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113828				\$351,638	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114147			\$233,306	\$233,306	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115126				\$503,276	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115198			\$639,588	\$1,266,585	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115877			\$25,979	\$854,713	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117432			\$132,804	\$415,847	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117461				\$185,285	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117799				\$27,278	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118513			\$234,566	\$553,990	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118790				\$12,222	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118932				\$10,200	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119169			\$385,443	\$574,860	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120877				\$271,827	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120992				\$665,502	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121125				\$505,380	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122096				\$387,706	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122174				\$553,752	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123052				\$472,613	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123066				\$286,188	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124688				\$158,199	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125417			\$532,102	\$1,361,562	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126227				\$291,544	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126417				\$110,922	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS127331				\$44,355	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128071				\$59,674	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128612			\$126,848	\$769,829	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129549			\$113,400	\$460,494	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129622				\$32,203	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129671				\$654,103	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS130297				\$39,293	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132128				\$138,940	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132326				\$168,091	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132330				\$11,333	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS133986				\$127,347	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS31744			\$241,180	\$479,309	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS76491			\$495,890	\$811,741	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS80168			\$2,615,683	\$4,546,476	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS84974			\$856,300	\$1,689,595	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS88627				\$342,017	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS89757				\$731,207	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92625				\$698,688	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS95495			\$21,799	\$747,077	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97273				\$1,280,553	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97495				\$135,133	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120605				\$28,304	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS095869	University of Cincinnati	NS095869		\$7,967	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100699	University of Cincinnati	NS100699		\$43,483	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS104095	University of Southern California	NS104095		\$8,792	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS104157	University of Chicago	NS104157		\$0	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107624	Yale University	NS107624		\$36,315	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS108916	Health Research, Inc.	NS108916		\$38,783	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110438	Columbia University	NS110438		\$316,686	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110728	University of Cincinnati	NS110728		\$1,349	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110772	University of Cincinnati	NS110772		\$14,619	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111039	Duke University	NS111039		\$16,304	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111981	Cleveland Clinic Foundation	NS111981		\$164,640	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112826	Yale University	NS112826		\$169,042	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113637	University of California—San Francisco	NS113637		\$224,270	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114552	University of Chicago	NS114552		\$50,799	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115388	Massachusetts General Hospital	NS115388	\$124,721	\$2,893,077	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115708	University of Pittsburgh	NS115708		\$12,920	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117450	University of Cincinnati	NS117450		\$12,861	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117844	Ohio State University	NS117844		\$173,743	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118669	Sun Health Research Institute	NS118669		\$68,326	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119587	Houston Methodist Research	NS119587		\$25,983	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119714	Scripps Research Institute	NS119714		\$120,642	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119834	The University of Texas Health	NS119834		\$214,460	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120331	St. Joseph Hospital	NS120331		\$22,657	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120496	University of Texas Southwest Medical Center	NS120496		\$21,521	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120557	Johns Hopkins University	NS120557		\$3,415	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120871	University of Cincinnati	NS120871		\$1,086	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120901	University of Utah	NS120901		\$104,006	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121720	Stanford University	NS121720		\$1,943	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121928	Case Western Reserve University	NS121928		\$46,687	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122226	Binghamton University	NS122226		\$13,201	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122419	New York University	NS122419		\$156,939	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122764	Johns Hopkins University	NS122764		\$32,453	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123743	Stanford University	NS123743		\$378,722	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123958	University of New Mexico	NS123958		\$65,243	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124065	University of Minnesota	NS124065		\$114,761	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125437	University of Minnesota	NS125437		\$170,216	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125895	Winco International, LLC	NS125895		\$161,654	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126609	University of Minnesota	NS126609		\$18,403	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS127187	University of Pittsburgh	NS127187		\$378,354	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128199	Medical College of Wisconsin	NS128199		\$105,655	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128964	University of California Los Angeles	NS128964		\$78,126	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129032	Massachusetts Institute of Technology	NS129032		\$21,405	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132146	Leland Stanford Junior University	NS132146		\$39,327	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132415	Harvard Medical School	NS132415		\$13,170	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92091	University of Miami	NS92091		\$52,916	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS93334	Boston University	NS93334		\$121,078	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS95869	University of Cincinnati	NS95869		\$19,653	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS96761	Carnegie Mellon University	NS96761		\$99,619	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97876	Columbia University	NS97876	\$116,016	\$272,517	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99043	University of Cincinnati	NS99043		\$26,541	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99043B	University of Cincinnati	NS99043B		\$15,989	\$42,574,214	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170478				\$130,543	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108682				\$464,490	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108891				\$375,708	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108906				\$317,781	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI110173				\$479,024	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120698				\$130,563	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI121054			\$7,199	\$269,593	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI122838				\$539	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI127365				\$381,656	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI128729			\$390,955	\$742,734	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI129191				\$120,468	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132165				\$46,413	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132348				\$527,090	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134937			\$48,878	\$771,867	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI136718			\$119,986	\$155,811	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI138965				\$225,630	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141765				\$183,685	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143791			\$155,759	\$585,294	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143882				\$186,491	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI146804				\$43,753	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI147652				\$299,391	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150100				\$487,077	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150649				\$28,985	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI151208			\$6,453	\$164,342	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI151923				\$57,879	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI152042			\$51,703	\$84,843	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154927				\$205,371	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI155378				\$126,121	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI156137			\$213,786	\$213,786	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI157328				\$15,091	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI158813				\$176,950	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI159230				\$147,431	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI161367				\$102,761	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI162678				\$457,111	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI169530			\$12,185	\$632,962	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170535			\$211,677	\$79,367	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170571				\$111,813	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170649				\$633,993	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI175039				\$199,104	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI175813				\$103,539	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI178943				\$93,871	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI181542				\$5,802	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI33144				\$245,545	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI48793				\$81,902	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI71106			\$202,032	\$661,175	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI89714				\$510,909	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI91594			\$128,171	\$382,592	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI176254				\$27,278	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132165				\$78,673	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
			Hennepin Healthcare Research Institute	75N91019D00024		\$32,973	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI104681	Duke University	AI104681		\$422,751	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI109565	Benaroya Research Institute	AI109565		\$242,649	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI110483	Emory University	AI110483		\$20,887	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI112844	University of Virginia	AI112844		\$12,924	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI116501	Washington University	AI116501		\$9,385	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
			Cincinnati Children's Hospital Medical Center	AI117804		\$17,492	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132402	University of Iowa	AI132402		\$69,377	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134770	University of Massachusetts	AI134770		\$119,849	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI138993	Arizona State University	AI138993		\$117,161	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141591	University of Michigan	AI141591		\$361,677	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
			Joan & Sanford I. Weill Medical College	AI144301		\$765	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI145108	University of Virginia	AI145108		\$233,039	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148963	ICAHN School of Medicine	AI148963		\$18,349	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154470	Boston Children's Hospital	AI154470		\$1,327	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154598	University of Virginia	AI154598		\$12,924	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
			Vanderbilt University Medical Center	AI154659		\$21,084	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI155907	Arizona State University	AI155907		\$36,106	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI162699	University of Minnesota	AI162699		\$30,117	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI164562	Emory University	AI164562		\$143,007	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI165061	Stinginn, LLC	AI165061		\$110,047	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI167700	Northeastern University	AI167700		\$48,723	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170424	Cedars Sinai Medical Center	AI170424		\$8,571	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
			Hennepin Healthcare Research Institute	AI171826		\$4,173	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI21747	University of Connecticut	AI21747		\$103,389	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI57266	Emory University	AI57266		\$369,268	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
			University of California Los Angeles	AI68636		\$34,361	\$15,157,172	RESEARCH AND DEVELOPMENT	\$445,961,340
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI68636				\$143,668	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144233				\$256,510	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM65841				\$330,149	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM063904			\$202,954	\$283,662	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM08685				\$369,043	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM126086			\$37,502	\$32,328	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM128253				\$366,789	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM130556			\$195,007	\$233,813	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132095			\$89,851	\$281,095	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132100				\$75,375	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM134732				\$256,391	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM135488				\$366,751	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136262				\$266,170	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136869				\$345,315	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM140487				\$418,148	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM141003			\$194,400	\$356,842	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM143949				\$211,121	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144233				\$340,172	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144351			\$204,822	\$389,820	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144393			\$203,263	\$446,117	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM145408				\$175,159	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM146651				\$306,508	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM147134							



MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM55252				\$43,860	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM75148				\$246,611	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
			University of Puerto Rico						
			Medical Center	GM137368		\$36,600	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM142122	Southcentral Foundation	GM142122		\$103,189	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM145385	University of North Florida	GM145385		\$1,245	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
			University of North Carolina at Chapel Hill	GM148971					
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM148971		GM148971		\$72,531	\$6,754,982	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	AR84222				\$293,823	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD102663				\$6,712	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103498			\$69,344	\$139,927	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD106096			\$370,351	\$521,038	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD112327				\$43,270	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD65987				\$459,219	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD99147				\$333,110	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HHS-N-275-2018-00005I			\$752,208	\$984,849	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD100540	Johns Hopkins University	HD100540		\$6,782	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD102615	Arizona State University	HD102615		\$245,067	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
			Massachusetts General Hospital	HD103099					
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103099		HD103099		\$37,365	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
			University of Kansas Medical Center	HD105714					
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105714		HD105714		\$63,450	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD107897	Sequitur Health Corporation	HD107897		\$54,101	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD108477	Binghamton University	HD108477		\$32,343	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD44763	University of Minnesota	HD44763		\$127,160	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
			University of Texas Medical Branch	HD84423					
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD84423		HD84423		\$214,799	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD86843	University of Pittsburgh	HD86843		\$36,869	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD87413	University of Virginia	HD87413		\$6,277	\$3,606,161	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG056366				\$350,459	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG058812				\$183,788	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG061796				\$520,806	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG062110				\$1,508,650	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG067593				\$809,017	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG06786			\$40,457	\$3,467,867	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG11378				\$863,378	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG13925			\$136,586	\$829,612	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG27924				\$291,708	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG37491				\$566,470	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG41851				\$236,717	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG44170			\$221,514	\$1,299,183	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG44615				\$432,856	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG45779				\$285,685	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG46139			\$1,502,787	\$2,550,564	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG46205				\$618,272	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG49672				\$159,564	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG50603				\$731,103	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG52425				\$72,120	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG53229				\$77,899	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG54199			\$130,782	\$886,015	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG54449				\$30,643	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG54454				\$222,039	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG55529			\$42,667	\$314,378	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG55549			\$36,528	\$712,990	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG56255			\$334,388	\$383,498	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG56366				\$45,156	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG57052				\$26,667	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG57181			\$-17	\$251,225	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG57493				\$20,122	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG58266			\$17,697	\$168,905	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG58738				\$329,103	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG58798				\$247,411	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG60637				\$244,753	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG60920				\$775,832	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG61456			\$469,321	\$917,921	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG62077				\$1,185,324	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG62104				\$134,714	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG62413			\$437,910	\$2,332,824	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG62436			\$85,815	\$474,986	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG62677				\$3,462,136	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG62859				\$601,483	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG63707				\$261,408	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG63780				\$358,253	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG63911			\$6,806,055	\$13,682,510	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG64029			\$61,385	\$197,880	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG64159				\$4	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG65143				\$8,130	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG65154			\$1,511,702	\$2,369,748	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG65219				\$236,897	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG65639				\$87,480	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG66395				\$692,795	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG66429				\$437,007	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG67593				\$352,054	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG67763			\$88,302	\$633,971	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68007				\$466,234	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68047				\$360,167	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68048				\$412,444	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68076				\$507,418	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68182				\$378,402	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68192				\$812,516	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68206				\$526,430	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68368				\$159,420	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68620				\$122,084	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG69052			\$34,135	\$893,166	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG69701			\$3,662,919	\$5,755,889	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG69767			\$134,927	\$387,243	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG70113				\$165,628	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG70486				\$24,840	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG71190				\$658,478	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG71226				\$392,452	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG71513				\$266,365	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG71686				\$416,216	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG71934				\$134,735	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG72301			\$280,536	\$494,566	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG72719				\$643,187	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG72898				\$383,942	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73282				\$366,350	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73525				\$130,754	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73726				\$257,441	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73967				\$190,786	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73987				\$127,554	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG74879			\$1,389,881	\$2,187,506	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG74883				\$214,788	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG75227			\$50,628	\$292,298	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG75802			\$1,731,663	\$4,273,594	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG76122			\$24,644	\$538,846	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG76163				\$326,676	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG76401				\$83,789	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG76469				\$319,002	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG76515			\$67,176	\$535,059	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG76537			\$85,122	\$425,500	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG76636				\$291,845	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG76662				\$174,680	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG77656				\$171,621	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG77706			\$290,527	\$702,567	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG77771			\$354,150	\$790,730	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG78179				\$163,440	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG78555				\$53,269	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG78615			\$271,181	\$460,702	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG79113			\$17,366	\$454,823	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG79859				\$265,216	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG80037				\$144,206	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG80556				\$299,418	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG81203			\$22,363	\$200,052	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG81223				\$96,517	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG81955				\$24,462	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG82314				\$93,962	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG82681				\$117,713	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG82704				\$49,159	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG82708				\$36,639	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG82919				\$40,302	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG85705				\$18,878	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG027161	University of Wisconsin Madison	AG027161		\$68,046	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG03949	Albert Einstein College of Medicine of Yeshiva University	AG03949		\$110,202	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG057437	University of Southern California	AG057437		\$77,629	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG06077	Innovative Design Labs Inc.	AG06077		\$70,660	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG061359	Duke University	AG061359		\$19,094	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG062348	Boston University	AG062348	\$25,000	\$110,122	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG078533	University of Texas at Austin	AG078533		\$33,998	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG23438	Washington University	AG23438		\$25,368	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG24904	University of California—San Diego	AG24904		\$988,056	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG32438	Washington University	AG32438		\$239,339	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG46139	University of Florida	AG46139		\$18,704	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG52350	University of Southern California	AG52350		\$4,428	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG53267	Washington University	AG53267		\$5,521	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG53798	University of Southern California	AG53798		\$63,256	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG54029	Massachusetts General Hospital	AG54029		\$245,377	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG54787	University of Mississippi Medical Center	AG54787		\$125,405	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG55469	Arizona State University	AG55469		\$1,205	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG56130	Sanford-Burnham Medical	AG56130		\$4,231	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG56270	Columbia University	AG56270		\$165,242	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG56318	Boston University	AG56318		\$284,259	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG56933	Johns Hopkins University	AG56933		\$17,007	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG57195	Indiana University	AG57195		\$828,589	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG57437	University of Southern California	AG57437		\$385,668	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG57708	Barrow Neurological Institute	AG57708		\$110,481	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG58676	University of Melbourne	AG58676		\$11,723	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG58729	Hennepin Healthcare Research	AG58729		\$24,660	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG59009	University of California—San Francisco	AG59009		\$13,648	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG59093	Duke University	AG59093		\$56,681	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG59417	California Pacific Medical Center Research Institute	AG59417		\$5,990	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG59798	Washington University	AG59798		\$66,624	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG60502	Johns Hopkins University	AG60502		\$82,322	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG60626	Dana-Farber Cancer Institute	AG60626		\$94,990	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG61100	Partners Health Care Res Mgmt	AG61100		\$173,017	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG61848	University of Southern California	AG61848		\$306,758	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG62135	University of Minnesota	AG62135		\$289,014	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG62171	Johns Hopkins University	AG62171		\$829,480	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG62689	University of California Berkeley	AG62689		\$101,560	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG62823	Arizona State University	AG62823		\$83,432	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG63689	University of Southern California	AG63689		\$531,935	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG64165	Brigham and Women's Hospital	AG64165		\$63,161	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG64271	Seattle Institute of Biomedical Clinical Research	AG64271		\$14,454	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG65088	Minnesota HealthSolutions Corporation	AG65088		\$166,710	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG65188	Duke University	AG65188		\$185,651	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG65204	American Federation For Aging Research	AG65204		\$6,866	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG65311	Beth Israel Deaconess Medical	AG65311		\$18,814	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG66134	Columbia University	AG66134		\$13,895	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG66768	Beth Israel Deaconess Medical Center	AG66768		\$6,406	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG67151	Massachusetts Institute of Technology	AG67151		\$199,622	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG67418	UCB Pharma, Inc.	AG67418		\$451,674	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG67631	Indiana University	AG67631		\$76,026	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68034	North Dakota State University	AG68034		\$132,336	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68054	University of Pittsburgh	AG68054		\$167,601	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68128	University of Florida	AG68128		\$58,905	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68141	Beth Israel Deaconess Medical	AG68141		\$35,270	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG68581	St. Jude Children's Hospital	AG68581		\$641,121	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG69264	University of Virginia	AG69264		\$4,164	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG69453	Banner Alzheimer's Institute	AG69453		\$222,514	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG69690	University of Texas	AG69690		\$126,337	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG69822	Yale University	AG69822		\$8,595	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG71754	Washington University	AG71754		\$1,516,621	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG71807	Wake Forest University Health Scienc	AG71807		\$10,219	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG72122	Washington University	AG72122		\$24,770	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG72799	University of Texas Houston	AG72799		\$47,933	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG72980	Banner Alzheimer's Institute	AG72980		\$164,195	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73119	University of Connecticut	AG73119		\$60,988	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73267	University of Pittsburgh	AG73267		\$103,450	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73341	Harvard University	AG73341		\$9,235	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73434	Georgia Institute of Technology	AG73434		\$51,520	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73482	University California San Francisco	AG73482		\$5,949	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG73886	Hebrew Rehabilitation Center	AG73886		\$9,629	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG74127	Minnesota HealthSolutions Corporation	AG74127		\$38,808	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG74867	University of Florida	AG74867		\$21,447	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG77677	University of Miami	AG77677		\$22,078	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG80469	Regents of the University of California at San Francisco	AG80469		\$5,695	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG81293	University of Pittsburgh	AG81293		\$7,835	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340

MAYO CLINIC  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG81582	Columbia University Medical Center	AG81582		\$2,115	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG84154	University of Missouri	AG84154		\$13,586	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
AGING RESEARCH	93.866	AG85900	University of Minnesota	AG85900		\$25,443	\$89,639,305	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY21727				\$120,174	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY31301				\$551,799	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY31758				\$187,420	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY35533				\$59,686	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY11751	Jaeb Center for Health Research	EY11751		\$7,844	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY14231	Jaeb Center for Health Research	EY14231		\$94,025	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY22124	Ohio State University	EY22124		\$130,314	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY23384	University of Minnesota	EY23384		\$160,117	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY26869	New York School of Medicine Jaeb Center for Health Research	EY26869		\$19,512	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY30030	Johns Hopkins University	EY30030		\$82,483	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY33293	University of Southern California	EY33293		\$4,487	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
VISION RESEARCH	93.867	EY35084		EY35084		\$314	\$1,418,175	RESEARCH AND DEVELOPMENT	\$445,961,340
MEDICAL LIBRARY ASSISTANCE	93.879	LM11934	University of Texas Health at Houston	LM11934	\$185,913	\$276,324	\$482,361	RESEARCH AND DEVELOPMENT	\$445,961,340
MEDICAL LIBRARY ASSISTANCE	93.879	LM13438	Arizona State University	LM13438		\$143,943	\$482,361	RESEARCH AND DEVELOPMENT	\$445,961,340
MEDICAL LIBRARY ASSISTANCE	93.879	LM13606	University of North Carolina	LM13606		\$43,007	\$482,361	RESEARCH AND DEVELOPMENT	\$445,961,340
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	MDH10327	Minnesota Department of Health	MDH10327		\$102,051	\$102,051	N/A	\$0
HIV CARE FORMULA GRANTS	93.917	GRK%212096	MN Department of Human Services	GRK%212096		\$181,596	\$181,596	RESEARCH AND DEVELOPMENT	\$445,961,340
TUBERCULOSIS DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION	93.947	PS910245				\$673,001	\$673,001	RESEARCH AND DEVELOPMENT	\$445,961,340
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	TW12265	Stellenbosch University	TW12265		\$4,316	\$4,316	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	75N91020F00030				\$109,419	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	75N91021P00840				\$141,726	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	75N94023F00001				\$175,833	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	75Q80120D00005				\$523,090	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	HHS-N-261-2012-00042I			\$15,199	\$55,094	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	HHS-N-261-2016-00024I				\$19,579	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	HHS-O-100-2016-00009C				\$20,072	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	16X237	Leidos Biomedical Research	16X237		\$457,046	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	75D30122C13330	Children's Hospital of Boston	75D30122C13330		\$12,612	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	75N91019C00016	Pact & Health LLC	75N91019C00016		\$57,001	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	75N91019D00024	Hennepin Healthcare Research Institute	75N91019D00024		\$340,745	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	75N92019D00031	Boston University	75N92019D00031		\$63,635	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	80JSC022F0146	University of Colorado	80JSC022F0146		\$47,066	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	HHNS-2-68-2018-00010I	University of Mississippi Medical Center	HHNS-2-68-2018-00010I		\$241,647	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	HHS-N-261-2012-00035I	Northwestern University	HHS-N-261-2012-00035I		\$13,859	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	HHS-N-261-2012-00042I	National Cancer Institute	HHS-N-261-2012-00042I		\$4,758	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	HHS-N-275-2018-00003I	Duke University	HHS-N-275-2018-00003I		\$16,936	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	HHS-P-233-2015-00128I	Carradora Health	HHS-P-233-2015-00128I		\$30,545	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	PC35143	University of Iowa	PC35143		\$165,120	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
CONTRACT	93.RD	W911QY-20-9-0012	Johns Hopkins University	W911QY-20-9-0012		\$266,975	\$2,762,758	RESEARCH AND DEVELOPMENT	\$445,961,340
MILITARY HEALTH PROFESSIONS SCHOLARSHIPS	93.U01	Office Of The Surgeon General				\$219,135	\$219,135	N/A	\$0

MAYO CLINIC  
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
 Fiscal Period 1/1/2023 - 12/31/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					\$51,257,275	\$409,783,328			
TOTAL EXPENDITURES OF FEDERAL AWARDS					\$54,435,304	\$465,627,082			
<i>See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance.</i>									



Schedule of Expenditures of Florida State Financial Assistance
Year Ended December 31, 2023

Table with 5 columns: Sponsor/CSFA Description/Project Description, CSFA Number, Contract / Grant / Subaward Number, Expenditures, Pass-Through to Subrecipients. Rows include STATE OF FLORIDA, Department of Elder Affairs, Department of Health, and Total Expenditures of State Financial Assistance.

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance

# Mayo Clinic

## Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance

December 31, 2023

### **1. Significant Accounting Policies**

The accompanying Schedules of Expenditures of Federal Awards and Florida State Financial Assistance (the Schedules) include the federal and Florida state grant activity of Mayo Clinic (the Clinic) under programs of the federal and Florida state government for the year ended December 31, 2023. The information in the Schedules is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the Uniform Guidance), and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Because the Schedules only present a selected portion of the operations of the Clinic, they are not intended to, and do not, present the consolidated financial position, results of operations, or cash flows of the Clinic.

Expenditures reported in the Schedules are reported on the cash basis of accounting, except for the Student Financial Assistance Cluster, which are reported on the accrual basis of accounting. Under the cash basis, expenditures are recognized when paid rather than when the obligation is incurred. Such expenditures are reported following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts reported on the Schedules represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

### **2. 10% De Minimis Cost Rate**

Indirect cost rates for Mayo are based on applicable U.S. Department of Health and Human Services negotiated rates, the 10% de minimis indirect cost rate allowed by the Uniform Guidance, or sponsor-specific (capped) rates.

### **3. Section 202 Direct Loans and Federal Direct Loans**

The Supportive Housing for the Elderly, Section 202 Direct Loans program (Assistance Listing No. 14.157), is considered a federal award until the outstanding balance is paid in full. At December 31, 2023, Bloomer Lakeview, Inc.'s outstanding balance is \$141,205.



## Mayo Clinic

### Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance (continued)

#### **3. Section 202 Direct Loans and Federal Direct Loans (continued)**

During the year, the Clinic expended \$18,063,580 in Federal Direct Student Loans (Assistance Listing No. 84.268), which includes Direct Stafford Loans and Parent Loans for Undergraduate Students from the federal government. The federal government is responsible for billings and collections of the loans. The Clinic assists the federal government by processing the applications and applying funds to student accounts from the federal government. Since this program is administered by the federal government, new loans made in the fiscal year ended December 31, 2023, related to Federal Direct Student Loans, are considered current year federal expenditures, whereas the outstanding loan balances are not.

# Uniform Guidance Reports and Schedule

## Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Board of Trustees, Chief Executive Officer and  
President, and Chief Financial Officer  
Mayo Clinic

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of Mayo Clinic (“the Clinic”), which comprise the consolidated statements of financial position as of December 31, 2023, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”), and have issued our report thereon dated February 16, 2024.

### **Report on Internal Control Over Financial Reporting**

In planning and performing our audit of the financial statements, we considered the Clinic’s internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Clinic’s internal control. Accordingly, we do not express an opinion on the effectiveness of the Clinic’s internal control.

*A deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements, on a timely basis. *A material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented, or detected and corrected on a timely basis. *A significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.



## Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Clinic's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

### Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

*Ernst + Young LLP*

February 16, 2024



Ernst & Young LLP  
Suite 500  
700 Nicollet Mall  
Minneapolis, MN 55402

Tel: +1 612 343 1000  
ey.com

Report of Independent Auditors on Compliance for Each Major Federal Program and State Financial Assistance Project and Report on Internal Control Over Compliance Required by the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*

Board of Trustees, Chief Executive Officer and  
President, and Chief Financial Officer  
Mayo Clinic

**Report of Independent Auditors on Compliance for Each Major Federal Program and State Financial Assistance Project**

***Opinion on Each Major Federal Program and State Financial Assistance Project***

We have audited Mayo Clinic’s (“the Clinic”) compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* and the Florida Department of Financial Services’ *State Projects Compliance Supplement* that could have a direct and material effect on each of the Clinic’s major federal programs and state financial assistance projects, respectively, for the year ended December 31, 2023. The Clinic’s major federal programs and state financial assistance projects are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Clinic complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs and major state financial assistance projects for the year ended December 31, 2023.

***Basis for Opinion on Each Major Federal Program and State Financial Assistance Project***

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance); and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Our responsibilities under those standards, the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida* are further described in the Auditor’s Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Clinic and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for each major federal program and state financial assistance project. Our audit does not provide a legal determination of the Clinic's compliance with the compliance requirements referred to above.

### ***Responsibilities of Management for Compliance***

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Clinic's federal programs and state projects.

### ***Auditor's Responsibilities for the Audit of Compliance***

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Clinic's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida* will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Clinic's compliance with the requirements of each major federal program and state financial assistance project as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Clinic's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.

- Obtain an understanding of the Clinic’s internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, but not for the purpose of expressing an opinion on the effectiveness of the Clinic’s internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

***Other Matters***

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida* and which are described in the accompanying schedule of findings and questioned costs, as follows:

<b>Finding No.</b>	<b>Assistance Listing or CSFA No.</b>	<b>Program (or Cluster) Name</b>	<b>Compliance Requirement</b>
2023-003	Multiple	Research and Development Cluster	M. Subrecipient Monitoring
2023-005	Multiple	Research and Development Cluster	I. Procurement, Suspension and Debarment

Our opinion on each major federal program and state financial assistance project is not modified with respect to these matters.

We performed audit procedures with respect to the Student Financial Assistance Cluster major federal program related to compliance requirements in Special Tests and Provisions N12, *Gramm-Leach Bliley Act – Student Information Security* as outlined in the *OMB Compliance Supplement* for the year ended December 31, 2023. We determined whether the Clinic has designated a “Qualified Individual,” as described in the *OMB Compliance Supplement*, to be responsible for implementing and monitoring the information security program in accordance with 16 CFR 314.4(a). We determined whether the Clinic has a written information security program and that the written information security program documents the seven minimum elements required by 16 CFR 314.4(a)-(g). Our audit procedures did not evaluate whether the designated Qualified Individual is competent to oversee the implementation and monitoring of the information security program nor whether the Qualified Individual possessed the adequate authority to carry out those duties. Our audit procedures also did not determine whether the written information security program sufficiently and completely addressed the seven minimum elements required by 16 CFR 314.4(a)-(g). Our opinion on the Student Financial Assistance Cluster major federal program is not modified with respect to this matter.

*Government Auditing Standards* requires the auditor to perform limited procedures on the Clinic’s response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The Clinic’s response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

## Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor’s Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance, and therefore, material weaknesses or significant deficiencies may exist that were not identified. However, as discussed below, we did identify certain deficiencies in internal control over compliance that we consider to be material weaknesses and significant deficiencies.

*A deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program or state financial assistance project on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program or state financial assistance project will not be prevented, or detected and corrected, on a timely basis. We consider the deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be material weaknesses as follows:

<b>Finding No.</b>	<b>Assistance Listing or CSEA No.</b>	<b>Program (or Cluster) Name</b>	<b>Compliance Requirement</b>
2023-002	Multiple	Research and Development Cluster	A. Activities Allowed or Unallowed; and B. Allowable Costs/Cost Principles
2023-003	Multiple	Research and Development Cluster	M. Subrecipient Monitoring
2023-004	Multiple	Research and Development Cluster	A. Activities Allowed or Unallowed; and B. Allowable Costs/Cost Principles
2023-004	64.130	Endowed Chair for Cancer Research Program	A. Activities Allowed or Unallowed; and B. Allowable Costs



<b>Finding No.</b>	<b>Assistance Listing or CSEA No.</b>	<b>Program (or Cluster) Name</b>	<b>Compliance Requirement</b>
2023-004	64.135	Ed and Ethel Moore Alzheimer's Disease Research Program	A. Activities Allowed or Unallowed; and B. Allowable Costs


A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program or state financial assistance project that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be significant deficiencies as follows:

<b>Finding No.</b>	<b>Assistance Listing No.</b>	<b>Program (or Cluster) Name</b>	<b>Compliance Requirement</b>
2023-001	84.268	Student Financial Assistance Cluster	N. Special Tests and Provisions: N12. Disbursements to or on Behalf of Students
2023-005	Multiple	Research and Development Cluster	I. Procurement, Suspension and Debarment

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

*Government Auditing Standards* require the auditor to perform limited procedures on the Clinic's response to the internal control over compliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The Clinic's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Accordingly, this report is not suitable for any other purpose.



June 25, 2024

Mayo Clinic

Schedule of Findings and Questioned Costs

For the Year Ended December 31, 2023

**Section I – Summary of Auditor’s Results**

**Financial Statements**

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP: Unmodified

Internal control over financial reporting:

Material weakness(es) identified?        **Yes**        X   **No**

Significant deficiency(ies) identified?        **Yes**        X   **None Reported**

Noncompliance material to financial statements noted?        **Yes**        X   **No**

**Federal Awards**

Internal control over major federal programs:

Material weakness(es) identified?   X   **Yes**             **No**

Significant deficiency(ies) identified?   X   **Yes**             **None Reported**

Type of auditor’s report issued on compliance for major federal programs:

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?   X   **Yes**             **No**

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

**Section I – Summary of Auditor’s Results (continued)**

Identification of major federal programs:

<u>Assistance Listing Numbers</u>	<u>Name of Federal Program or Cluster</u>
Multiple 84.063 and 84.268	Research and Development Cluster Student Financial Assistance Cluster

Dollar threshold used to distinguish between Type A and Type B programs: \$ 3,000,000

Auditee qualified as low-risk auditee?        **Yes**        X   **No**

**Florida State Financial Assistance Projects**

Internal control over major state financial assistance projects:

Material weakness(es) identified?   X   **Yes**             **No**

Significant deficiency(ies) identified?        **Yes**        X   **None Reported**

Type of auditor’s report issued on compliance for major state financial assistance projects: Unmodified

Any audit findings disclosed that are required to be reported in accordance with Chapter 10.650, *Rules of the Auditor General of the State of Florida*?   X   **Yes**             **No**

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

**Section I – Summary of Auditor’s Results (continued)**

Identification of major state projects:

<b>State CSFA Numbers</b>	<b>Name of State Project</b>
64.130	Endowed Chair for Cancer Research
64.135	Ed and Ethel Moore Alzheimer’s Disease Research Program
Dollar threshold used to distinguish between Type A and Type B programs:	<hr/> \$686,300 <hr/>

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

**Section II – Financial Statement Findings**

None identified.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs**

##### **Finding 2023-001 – N2 Disbursements to or on Behalf of Students**

*Identification of the federal program:*

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Assistance Listing No.: 84.268, Federal Direct Student Loans (Direct Loans)

Award Periods: July 1, 2022 through June 30, 2023; July 1, 2023 through June 30, 2024

*Criteria or specific requirement (including statutory, regulatory or other citation):*

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

*Condition:*

When Direct Loans are being credited to a student’s account, an institution must notify the student, or parent, in writing of (1) the date and amount of the disbursement; (2) the student’s right, or parent’s right, to cancel all or a portion of that loan or loan disbursement and have the loan proceeds returned to the holder of that loan; and (3) the procedure and time by which the student or parent must notify the institution that he or she wishes to cancel the loan. In order to identify these students, Mayo Clinic (“the Clinic”) utilizes a disbursement report that is run from a script housed in SAP Business Objects. Information technology general controls (ITGCs) over the SAP Business Objects disbursement report was not tested by the Clinic during 2023 to ensure the accuracy and completeness of the disbursement report.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

*Cause:*

Information technology general controls were not tested for SAP Business Objects in 2023.

*Effect or potential effect:*

The disbursement report may be inaccurate or incomplete and as a result a student may not be timely notified of the date and amount of the disbursement; the student/parent's right to cancel; and the procedure and time by which the student or parent must notify the institution that he or she wishes to cancel.

*Questioned costs:*

None.

*Context:*

Total expenditures for the Student Financial Assistance Cluster were \$18,084,644 for the year ended December 31, 2023.

*Identification as a repeat finding, if applicable:*

This finding is not a repeat finding from the prior year.

*Recommendation:*

The Clinic should implement internal controls to ensure SAP Business Objects ITGCs are tested or implement compensating controls to ensure the disbursement report is accurate and complete.

*Views of responsible officials:*

The Clinic has internal controls over access and change management procedures in place over Business Objects. Management will ensure these controls are tested annually.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

#### **Finding 2023-002 – Activities Allowed or Unallowed and Allowable Costs/Cost Principles**

*Identification of the federal program:*

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense

Pass-Through Entities: Georgia Institute of Technology, Massachusetts General Hospital, NYU Grossman School of Medicine, University of Chicago, University of Michigan, and Washington University

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 93.233, 93.273, 93.279, 93.310, 93.350, 93.393, 93.395, 93.396, 93.397, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.865, and 93.866

Award Numbers: Various

Award Periods: Various

*Criteria or specific requirement (including statutory, regulatory or other citation):*

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

*Condition:*

Evidence of review of allowability of internal service charges at a transactional level by the Principal Investigator (PI) or appropriate individual with authority on the grant was not retained during the fiscal year.



## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

*Cause:*

While internal service charges transaction detail is reviewed for allowability with federal regulations and the terms and conditions of the grant award on a monthly/quarterly basis by the PI as part of the grant's financial statement review, evidence of the monthly/quarterly review by the PI and conclusions reached over allowability was not retained by the Clinic during fiscal year 2023.

*Effect or potential effect:*

Internal service costs could be charged that are not allowable.

*Questioned costs:*

None.

*Context:*

Internal service charges are \$49,405,925, representing 11.1% of total Federal expenditures for the R&D Cluster of \$445,961,340 for the year ended December 31, 2023.

*Identification as a repeat finding, if applicable:*

The finding is a repeat of Finding 2022-007 in the prior year.

*Recommendation:*

Beginning in fiscal year 2024, the PI monthly/quarterly review packet was redesigned to provide evidence of review and conclusions reached over internal service charges transaction detail. Management should ensure that the newly implemented control is operating as designed.

*Views of responsible officials:*

Management implemented revisions to the monthly/quarterly review packet in January 2024 to provide evidence of review and conclusions reached over the allowability of internal service charges. Communication has occurred to ensure awareness and understanding of control process expectations.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

##### **Finding 2023-003 – Subrecipient Monitoring**

###### *Identification of the federal program:*

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.RDC, 12.300, 93.393, 93.396, 93.847, 93.853, 93.859

Award Numbers: Various

Award Periods: Various

###### *Criteria or specific requirement (including statutory, regulatory or other citation):*

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government,” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Section 200.332(d) of the Uniform Guidance states:

“Monitor the activities of the subrecipient as necessary to ensure that the subaward is used for authorized purposes, in compliance with Federal statutes, regulations, and the terms and conditions of the subaward; and that the subaward performance goals are achieved. Pass-through entity monitoring of the subrecipient must include:

(1) Reviewing financial and performance reports required by the pass-through entity.”

Furthermore, it is the Clinic’s policy for principal investigators to complete a subaward monitoring checklist as part of the monthly/quarterly reviews of subrecipient performance.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

*Condition:*

Subaward monitoring checklists were not consistently completed or retained to evidence the results of the monitoring performed over subrecipients by principal investigators during the fiscal year.

*Cause:*

Established internal controls over the completion of the subaward monitoring checklist as part of the monthly/quarterly reviews were not followed during the fiscal year.

*Effect or potential effect:*

Subrecipients may not be monitored timely. Subaward may not be used for authorized purposes, or performance goals may not be achieved by the subrecipient.

*Questioned costs:*

None.

*Context:*

We sampled 40 subaward monitoring checklists required to be completed during fiscal year 2023 by various principal investigators and noted the following related to the subaward monitoring checklist:

- Not included with the monthly/quarterly review materials (2 instances),
- Not completed due to retirement of the principal investigator (1 instance),
- Not completed timely during fiscal year 2023 (10 instances)
  - Subaward monitoring checklists are included in regular financial reviews which were delayed due to implementation of a new general ledger system effective April 1, 2023. Various Q3 and Q4 2023 subaward monitoring checklists were not completed until Q1 2024.

Subrecipient expenditures are \$54,435,304, representing 12.2% of total Federal expenditures for the R&D Cluster of \$445,961,340 for the year ended December 31, 2023.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

*Identification as a repeat finding, if applicable:*

This finding is not a repeat finding from the prior year.

*Recommendation:*

The Clinic should ensure that the subrecipient monitoring checklist is completed timely and documentation is retained to support the operating effectiveness of established internal controls.

*Views of responsible officials:*

Subaward monitoring checklists are included in monthly/quarterly reviews, which were delayed during the last half of 2023 due to the implementation of a new general ledger system effective April 1, 2023. Monthly/quarterly reviews resumed in January 2024. Communication has occurred to reiterate control process expectations.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

#### **Finding 2023-004 – Activities Allowed or Unallowed and Allowable Costs/Cost Principles**

##### *Identification of the federal program:*

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense

Pass-Through Entities: Boston University, Georgia Institute of Technology, Massachusetts General Hospital, NYU Grossman School of Medicine, Stanford University, The University of Texas, University of Buffalo, University of Chicago, and Washington University

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 93.233, 93.273, 93.279, 93.310, 93.350, 93.393, 93.395, 93.396, 93.397, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, and 93.866

Award Numbers: Various

Award Periods: Various

##### *Identification of the state projects:*

State Grantor: State of Florida Department of Health (DOH)

Catalog of State Financial Assistance (CSFA) No.: 64.130, Endowed Chair for Cancer Research

Award Number: MOG07

Award Period: July 1, 2014 – until expended

State Grantor: State of Florida Department of Health (DOH)

Catalog of State Financial Assistance (CSFA) No.: 64.135, Ed and Ethel Moore Alzheimer's Disease Research Program

Award Numbers: 20A10, 22A04, 22A05, 22A06, 22A07, 22A08, 22A09, 22K01, 23A03, 23A04, and 23K09

Award Periods: Various

##### *Criteria or specific requirement (including statutory, regulatory or other citation):*

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

“The Non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Section 215.97, Florida Single Audit Act, part (2)(j) states, “Internal control over state projects means a process, effected by a nonstate entity’s management and other personnel, designed to provide reasonable assurance regarding the achievement of objectives in the following categories:

1. Effectiveness and efficiency of operations.
2. Reliability of financial operations.
3. Compliance with applicable laws and regulations.”

*Condition:*

Internal controls over effort reporting were not operating effectively from April 1, 2023 through May 31, 2023 and, therefore, could not be relied upon.

Internal controls over salary cap were not operating effectively from April 1, 2023 through December 31, 2023 and therefore, could not be relied upon.

*Cause:*

The Clinic implemented a new general ledger system effective April 1, 2023. The general ledger implementation necessitated a rewrite of the effort certification system which delayed certification for the months of April and May. Therefore, for the period April 1, 2023 through May 31, 2023, effort certifications were not performed monthly.

The information technology application used to calculate salary cap adjustments to salary expenses resulting from the effort certification process was not functioning as designed from April 1, 2023 through December 31, 2023.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

*Effect or potential effect:*

Salary cap adjustments to payroll costs charged to the federal program may not be recorded timely.

Unallowable payroll costs may be charged to the federal program or state project.

*Questioned costs:*

None.

*Context:*

Payroll and fringe benefit expenditures are \$163,912,932, representing 36.8% of total Federal expenditures for the R&D Cluster of \$445,961,340 for the year ended December 31, 2023.

Payroll and fringe benefit expenditures are \$289,963, representing 30.8% of total state expenditures for CSFA 64.130 of \$940,679 for the year ended December 31, 2023.

Payroll and fringe benefit expenditures are \$551,321, representing 67.5% of total state expenditures for CSFA 64.135 of \$816,958 for the year ended December 31, 2023.

*Identification as a repeat finding, if applicable:*

This finding is not a repeat finding from the prior year.

*Recommendation:*

Management should ensure effort report certifications and approvals are performed monthly. In addition, management should review the design of the payroll salary cap application to ensure it is appropriately calculating salary expenses during the effort certification process.

*Views of responsible officials:*

Effort certification was delayed for the months of April and May 2023. No certification periods in 2023 were missed and the effort certification system is operating as designed as of July 17, 2023.

Manual reconciliations of the salary cap application were performed on every award for fiscal year 2023 to ensure salaries were correctly charged. The salary cap application is working effectively as of January 1, 2024.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

##### **Finding 2023-005 – Procurement, Suspension and Debarment**

*Identification of the federal program:*

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense

Federal Cluster: Research and Development (R&D)

Pass-Through Entity: The University of Texas Health (93.853, NS119834)

Assistance Listing Nos.: 12.420, 93.310, 93.353, 93.393, and 93.853

Award Numbers: W81XWH-15-1-0292 (12.420), OD23121 (93.310), CA246568 (93.353), CA259201 (93.393), NS119834 (93.853), NS122096 (93.853)

Award Periods: Various

*Criteria or specific requirement (including statutory, regulatory or other citation):*

Section 200.303 of the Uniform Guidance states the following regarding internal control:

“The Non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Section 200.320(a)(2)(i) of the Uniform Guidance states the following regarding small purchases:

“The acquisition of property or services, the aggregate dollar amount of which is higher than the micro-purchase threshold but does not exceed the simplified acquisition threshold. If small purchase procedures are used, price or rate quotations must be obtained from an adequate number of qualified sources as determined appropriate by the non-Federal entity.”

Section 200.320(b) of the Uniform Guidance states the following regarding formal procurement methods to be followed:



## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

“When the value of the procurement for property or services under a Federal financial assistance award exceeds the simplified acquisition threshold (SAT), or a lower threshold established by a non-Federal entity, formal procurement methods are required. Formal procurement methods require following documented procedures. Formal procurement methods also require public advertising unless a non-competitive procurement can be used in accordance with § 200.319 or paragraph (c) of this section.”

Section 200.214 of the Uniform Guidance states “Non-Federal entities are subject to the non-procurement debarment and suspension regulations implementing Executive Orders 12549 and 12689, 2 CFR part 180. The regulations in 2 CFR part 180 restrict awards, subawards, and contracts with certain parties that are debarred, suspended, or otherwise excluded from or ineligible for participation in Federal assistance programs or activities.”

The Clinic procurement justification form for procurements more than \$25,000 requires completion of the rationale for the procurement and a search of the federal government’s exclusion list to be performed and documented at the time of the procurement.

On a monthly basis, Supply Chain Management performs a review of completed procurement justification forms related to procurements > \$25,000 to ensure they are documented in accordance with the Clinic’s procurement, suspension and debarment policies and procedures.

*Condition:*

#### Internal Control

For five (56%) of nine procurement transactions tested for operating effectiveness of internal controls, the procurement justification form used by the Clinic to document the history of the procurement and compliance with Uniform Guidance CFR 200.303, was not completed until after the purchase order was created and/or invoice received from the vendor. In addition, for these same five procurement transactions, the Clinic did not timely document its suspension and debarment check at the time of procurement as required by its procurement justification form.

In addition, for four (44%) of nine procurement transactions tested for operating effectiveness of internal controls (two of which relate to the five cited above), the procurement justification form used by the Clinic to document the procurement transaction’s compliance with policies, procedures and the Uniform Guidance was outdated.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

Furthermore, the monthly review of completed procurement justification forms related to procurements > \$25,000 to ensure they are documented in accordance with the Clinic's procurement, suspension and debarment policies and procedures was not operating effectively.

#### Compliance

For one (9%) of 11 procurement transactions tested for compliance, the procurement was an add-on purchase related to a larger procurement of the same product under a prior purchase order. The prior procurement was above the simplified acquisition threshold and the Clinic's competitive bid threshold. The Clinic did not complete a procurement justification form for the add-on purchase (which was a small purchase), and the original procurement did not have adequate support to evidence that it had been competitively bid. As such, adequate documentation did not exist for the procurement in accordance with Uniform Guidance Section 230.320(a)(2)(i) and(b).

In addition, for five procurement transactions, the Clinic did not follow its suspension and debarment procedures as required by its procurement justification form.

#### *Cause:*

While management has internal controls in place to review procurements > \$25,000 to ensure they are documented in accordance with the Clinic's procurement, suspension and debarment policies and procedures and Uniform Guidance CFR 200.320, the review of the procurement justification form is not robust enough to identify errors and there is not a process in place to ensure the form is completed prior to the purchase.

#### *Effect or potential effect:*

The Clinic's internal controls over procurement were not properly followed during the fiscal year. In addition, the Clinic did not follow the Uniform Guidance requirements related to small purchases and noncompetitive procurements.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

##### *Questioned costs:*

\$53,482, determined as the amount of the procurement expenditures included in the schedule of expenditures of federal awards for the year ended December 31, 2023, for the one procurement transaction that had inadequate support for compliance with CFR 200.320 at the time of procurement, as follows:

- Assistance Listing No. 93.310, OD023121 – \$53,482

##### *Context:*

##### Internal Control

We sampled nine federal procurements over \$25,000 to test operating effectiveness of internal controls, totaling \$962,393, from a population of 74 federal procurements over \$25,000, totaling \$5,400,242 and noted the following:

- For seven of the 11 federal procurements tested totaling \$770,093, procurement controls were not operating effectively.
- For five of 11 procurement transactions tested totaling \$529,273, the independent suspension and debarment check to be performed at the time of procurement was not performed until approximately two to eight months later.

##### Compliance

We sampled 11 federal procurements over \$25,000 to test compliance, totaling \$1,736,844, from a population of 74 federal procurements over \$25,000, totaling \$5,400,242 and noted the following:

- For one of 11 federal procurements tested totaling \$53,482, documentation retained was not adequate to support that the procurement transaction was executed in accordance with the Uniform Guidance Sections 200.320(a)(2)(i) and (b).
- For five of 11 procurement transactions tested totaling \$529,273, the Clinic did not follow its suspension and debarment procedures as required by its procurement justification form.

## Mayo Clinic

### Schedule of Findings and Questioned Costs (continued)

#### **Section III – Federal Award and State Project Findings and Questioned Costs (continued)**

Procurement-related expenditures are approximately 9% of total Federal expenditures for the R&D Cluster of \$445,961,340 for the year ended December 31, 2023.

*Identification as a repeat finding, if applicable:*

The finding is not a repeat of the finding of the prior year.

*Recommendation:*

The Clinic should ensure that all R&D awards that require procurement of goods and services follow established policies, procedures, and internal controls to comply with the Uniform Guidance procurement standards and that the procurement justification form is reviewed prior to entering into the purchase transaction. The Clinic should ensure that independent checks for suspension and debarment should be timely completed at the time of procurement in accordance with the Clinic documented policies, procedures, and internal controls.

*Views of responsible officials:*

Management will reinforce education and training to the research community and procurement teams regarding the procurement requirements, Justification of Source Selection Checklist/Form, and timely completion of the required documentation.

The Clinic utilizes a third party, Visual Compliance, to execute daily supplier sanction and debarment checks for all Mayo Clinic vendors. All third party suspension and debarment match alerts are reviewed and adjudicated as needed. Going forward, the Clinic will supplement this daily review by periodically validating a sample of vendors who are not flagged with an alert by Visual Compliance.

## **EY | Building a better working world**

**EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.**

**Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.**

**Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.**

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via [ey.com/privacy](https://ey.com/privacy). EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit [ey.com](https://ey.com).

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2024 Ernst & Young LLP.  
All Rights Reserved.

**[ey.com](https://ey.com)**

---

**Summary Schedule of Prior Audit Findings – For the Years Ended December 31, 2022 and 2021****Finding 2022-001 – Information Technology General Controls***Identification of the federal program:*

Federal Agency: United States Department of Education

Federal Cluster/Program: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

**Summary of Prior Audit Finding***Condition:*

Mayo Clinic (the Clinic) did not implement all Complementary User Entity Controls (CUECs) as prescribed in the Ellucian SOC 1 Report that are required to be in place to support effective information technology general controls (ITGCs) for the Banner application. The controls that were not specifically implemented relate to user access review. Additionally, user provisioning and user termination processes were not operating as designed. As a result, Banner ITGCs cannot be relied upon in the period of audit.

There is a risk the data relevant to the SFA Cluster program stored within the student financial aid system may be inappropriately created or modified. A user access review was not performed during the current period. For the remainder of the CUECs, evidence of the operation of controls identified to address this risk during the fiscal period under audit was not appropriately retained.

*Recommendation:*

Management should complete the implementation for all required CUECs prescribed within the Ellucian SOC 1 Report and retain documentation of the operation of controls.

**Status**

Completed. Mayo Clinic IT worked with the Student Financial Aid office to review the risk rating given to the Banner application. A complete user access review based on job roles was completed in 2023. The review included each employee's assigned functions within the Banner system. The user provisioning process was updated to include the functions the user is receiving.

Enhanced documentation is now retained for user terminations and other system reports required to complete testing of the Banner controls.

**Contact Person**

Alec Haws, ETC Education Application Analyst

Raj Sanwal, Lead IT Analyst/Programmer

**Finding 2022-002 – Procurement, Suspension and Debarment***Identification of the federal program:*

Federal Agency: U.S. Department of Health and Human Services

Federal Cluster: Research and Development (R&D)

Pass-Through Entities: University of Iowa (93.397) and NYU Grossman School of Medicine (93.838)

Assistance Listing Nos.: 93.310, 93.394, 93.397 and 93.838

Award Numbers: OD23121, CA212162, CA97274 and HL16847

Award Periods: Various

## **Summary of Prior Audit Finding**

### *Condition:*

Four federal procurements conducted in fiscal year 2022 in excess of the SAT of \$250,000 were not competitively bid as required under Uniform Guidance Section 230.320(b) nor was a competitive bid exception documented to support the lack of formal proposals in accordance with Clinic procurement policies and procedures and Uniform Guidance Section 230.320(c). In addition, for one procurement, the Clinic did not timely document its independent suspension and debarment check at the time of procurement as required by its procurement justification form.

### *Recommendation:*

The Clinic should ensure that all R&D awards that require procurement of goods and services follow established policies, procedures and internal controls in order to comply with the Uniform Guidance procurement standards. The Clinic should ensure that independent checks for suspension and debarment should be timely completed at the time of procurement in accordance with Clinic documented policies, procedures and internal controls.

## **Status**

Completed. The procurement policies and procedures were reviewed and no changes were needed however, the appropriate education has been completed with Supply Chain Management staff to review and educate them on the federal bid requirements. A checkpoint was also added to communicate expectations on determining when a project is federally funded. In addition, the Audit, Controls, & Finance Team does a monthly review of federal purchases over \$25,000 to ensure proper documentation is retained.

## **Contact Person**

Bruce Mairose, SCM Division Chair, Sourcing/Network Management

## **Finding 2022-003 (and 2021-006) – Gramm-Leach-Bliley Act – Student Information Security (GLBA)**

### *Identification of the federal program:*

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

## **Summary of Prior Audit Finding**

### *Condition:*

The Clinic has a security risk program in place that follows the National Institute of Standards and Technology (NIST) framework to assess its information technology risks. The program includes: (1) employee training and management; (2) information systems, including network and software design, as well as information processing, storage, transmission, and disposal; and (3) detecting, preventing, and responding to attacks, intrusions, or other systems failures.

However, for the student financial aid system used by the Clinic, the 2022 NIST risk assessment did not cover (2) information systems, including network and software design, as well as information processing, storage, transmission, and disposal; and (3) detecting, preventing, and responding to attacks, intrusions, or other systems failures.

### *Recommendation:*

We recommend that the Clinic include the student information systems as part of its annual

enterprise-wide risk assessment.

**Status**

Completed. The following steps have been completed to address the gap identified:

1. Compared the scope of the Mayo Clinic Information Security annual risk assessment and the requirements of the Department of Education, under the Gramm-Leach-Bliley Act and identified any gaps.
2. Edited the existing annual risk assessment to close the gaps.
3. Completed the risk assessment.

**Contact Person**

Sarah Tyson, Senior Manager – Office of Information Security

**Finding 2022-004 (and 2021-007) – Enrollment Reporting**

*Identification of the federal program:*

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Period: July 1, 2021 through June 30, 2022

**Summary of Prior Audit Finding**

*Condition:*

As part of the review of the monthly SFRNSLC enrollment report prior to its upload to the National Student Clearinghouse (NSC)/National Student Loan Data System, the Financial Aid Director sampled 10 students from the monthly SFRNSLC enrollment report for accuracy against the student records system and sampled 10 students from the student records system for completeness against the monthly SFRNSLC enrollment report. However, evidence was not retained of the students sampled and the specific data validated as part of the review for the period January 1 – June 30, 2022. Management implemented internal controls on July 1, 2022 to include the retention of documentation over its internal controls. This control was tested for the period July 1, 2022 through December 31, 2022 and determined to be operating effectively.

*Recommendation:*

Management should continue to follow its internal control implemented on July 1, 2022 which documents the review process performed by the Financial Aid Director, including the students sampled and specific data validated, the results of the review, and the follow-up actions taken, if any, and sign-off by the Financial Aid Director to evidence performance of the monthly review.

**Status**

Completed. Management retains evidence to support internal controls implemented as of July 1, 2022, to document the review process performed for data submitted to the National Student Loan Clearinghouse, including the students sampled and specific data validated, the results of the review, and the follow-up actions taken, if any, and sign-off by the Financial Aid Director to evidence performance of the monthly review.

**Contact Person**

Anne Dahlen, Director of Student Financial Aid/Registrar

Delores Henke, Assistant Registrar



**Finding 2022-005 (and 2021-008) – Activities Allowed or Unallowed and Eligibility (Cost of Attendance)**

*Identification of the federal program:*

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

**Summary of Prior Audit Finding**

*Condition:*

Annual cost of attendance (COA) budgets (by program/by enrollment status) uploaded to Mayo Clinic College of Medicine and Science’s student information system by the Program Manager of Student Financial Aid were not reviewed and approved by another individual for accuracy once the upload was complete for the period January 1 – August 31, 2022. Management implemented internal controls on September 1, 2022 to include evidence over review and approval of COA budgets and performed the control for any remaining programs for which COA budgets required upload to the student information system by December 31, 2022. This control was tested for the period September 1, 2022 through December 31, 2022 for two of four programs subject to the new control and determined to be operating effectively.

*Recommendation:*

Management should continue to follow its internal control implemented on September 1, 2022 which requires signoff on the annual COA budgets uploaded into the student information system by the Program Manager of Student Financial Aid by a secondary reviewer to ensure accuracy.

**Status**

Completed. Annual cost of attendance budgets uploaded to Mayo Clinic College of Medicine and Science’s student information system by the Program Manager of Student Financial Aid are reviewed and approved by another individual for accuracy once the upload is complete.

**Contact Person**

Anne Dahlen, Director of Student Financial Aid/Registrar

Maribeth Foerster, Program Manager Student Financial Aid

**Finding 2022-006 – Reporting**

*Information of the state program:*

State Grantor: State of Florida Department of Health (DOH)

Catalog of State Financial Assistance (CSFA) No.: 64.130, Endowed Chair for Cancer Research

Award Number: MOG07

Award Period: 07/01/2014 – 06/30/2023

**Summary of Prior Audit Finding**

*Condition:*

The annual progress report required by the State of Florida DOH was not submitted timely and no approved extension was obtained. Additionally, there was an error in the amounts reported for Endowment Expenditures and Endowment Balance for one of seven activities under Award Number MOG07.

*Recommendation:*

The Clinic should implement an internal control over the monitoring of due dates of all reports required to be submitted under the State of Florida DOH project to ensure they are reviewed and

submitted timely. When required, formal extensions of reporting deadlines should be obtained from the State of Florida DOH. In addition, review controls should be designed with sufficient precision to ensure accuracy of amounts reported in the annual progress report.

**Status**

Completed. The statute requiring an annual progress report of award MOG07 has been repealed effective 7/1/23 in Chapter 2023-246 of House Bill No. 5303. Mayo Clinic Government Engagement, Research Administration and Research Finance will partner to create a control for any future reporting required to the Florida Department of Health.

**Contact Person**

Layne Smith, Communication-Policy and Engagement  
Brian Hultgren, Research Administration  
Sarah Ward, Research Finance

**Finding 2022-007 (and 2021-001) – Activities Allowed or Unallowed and Allowable Costs/Cost Principles**

**(Internal Service Charges)**

*Identification of the federal program:*

Federal Agency: U.S. Department of Health and Human Services

Pass-Through Entities: University of Iowa (Assistance Listing No. 93.397), Massachusetts General Hospital (Assistance Listing No. 93.853), and UCB Pharma, Inc. (Assistance Listing 93.866)

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 93.350, 93.393, 93.394, 93.395, 93.397, 93.837, 93.847, 93.853, and 93.866

Award Numbers: Various

Award Periods: Various

**Summary of Prior Audit Finding**

*Condition:*

Approval of allowability of internal service charges by the Principal Investigator (PI) or appropriate individual with authority on the grant was not consistently maintained at a transactional level during the fiscal year.

*Recommendation:*

The Clinic should retain sufficient evidence of the monthly/quarterly review of internal service charges by PIs and the related conclusions reached over allowability.

**Status**

Completed. Information Technology work is complete requiring that 1) the Principal Investigator, or authorized lab personnel, initiates new requests for service, 2) the intake process captures the requestor and project to be charged, and 3) confirmation is received before work begins. In addition, Research Finance is implementing new processes to ensure the review of internal service charges are adequately documented.

**Contact Person**

Sean Corcoran, Section Head – Information Technology, Research Applications  
Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance  
Kristine Williams, Operations Administrator – Research Administrative Services

## **Finding 2021–002**

### **Federal Program Information**

Federal Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund (COVID-19 Uninsured Program)

Award Numbers: Various

Award Period: January 1, 2021 through December 31, 2021

### **Summary of Prior Audit Finding**

Condition:

The Clinic did not document its compliance with the HRSA COVID-19 Uninsured Program T&Cs.

For certain emergency department and physician office visits that included COVID-19 testing, but COVID-19 was not the primary reason for the related treatment visit and services, the Clinic erroneously billed the HRSA COVID-19 Uninsured Program for the entire encounter, which was not in compliance with the HRSA COVID-19 Uninsured Program regulations.

Internal controls over the determination of a patient's uninsured/self-pay status were not operating effectively. In addition, inadequate support was retained in the patient billing and recordkeeping system related to the determination of the patient's uninsured/self-pay status and in some instances, no support was retained.

Refunds required to be made to the HRSA COVID-19 Uninsured Program were not identified.

Furthermore, a risk exists that the data relevant to the HRSA COVID-19 Uninsured Program stored within the patient accounting system may be inappropriately created or modified. Evidence of the operation of controls identified to address this risk during the fiscal period under audit was not retained.

Recommendation:

The Clinic should implement internal controls to document its review and compliance with the HRSA COVID-19 Uninsured Program T&Cs.

The Clinic should implement sufficiently precise internal controls to review changes to the HRSA COVID-19 Uninsured Program to ensure it is administering the program in compliance with the HRSA COVID-19 Uninsured Program regulations. In addition, internal controls should be implemented to ensure claims submitted to the HRSA COVID-19 Uninsured Program meet the allowability criteria established by the HRSA COVID-19 Uninsured Program regulations before claims are submitted to HRSA for reimbursement.

Standard policies, procedures, and internal controls over the review for patient insurance coverage and review of credit balances should be updated to address the unique aspects of the HRSA COVID-19 Uninsured Program.

Management should retain documentation of the operation of controls responsive to risks related to the data stored in their IT systems as evidence of control activities.

**Status**

Completed. A comprehensive review of the coverage rules in Mayo Clinic's Electronic Health Record (EHR) related to the HRSA COVID-19 Uninsured Program has been completed. EHR billing edits were put in place to review claims prior to submission and ensure compliance with the HRSA COVID-19 Uninsured Program. A review of all HRSA COVID-19 Uninsured Program payments made from 2020 through April 30, 2022 were evaluated to ensure compliance with the HRSA COVID-19 Uninsured Program T&Cs. Refunds were identified in the review process and have been expeditiously refunded according the HRSA COVID-19 Uninsured Program requirements.

**Contact Person**

Sharon M. Kelley, Chair – Revenue Cycle  
Michelle Densley, Director – Revenue Compliance

**Finding 2021–003****Federal Program Information**

Federal Agencies: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 12.RD, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.884, and 93.RD

Award Numbers: Various

Award Periods: Various

**Summary of Prior Audit Finding**

Condition:

The Clinic maintains a monthly balanced scorecard to monitor that that subrecipient risk assessment are being completed timely. For 8 of 12 months during the fiscal year, there was no evidence of review and approval of the calculated metric.

The Clinic's principal investigators perform monthly/quarterly reviews of subrecipient financial and performance reports; however, documentation was not consistently completed or retained to evidence the results of the monitoring during the fiscal year.

Recommendation:

The Clinic should ensure that evidence is retained to support the operating effectiveness of established internal controls.

**Status**

Completed. Management has remediated review and approval of the balanced scorecard beginning in 2022. Management implemented corrective actions immediately following completion of the 2020 single audit in March of 2022. Those corrective actions ensure that proper documentation has been and will continue to be retained to support the operating effectiveness of established internal controls.

**Contact Person**

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

## **Finding 2021–004**

### **Federal Program Information**

Federal Agencies: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 12.RD, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.884, and 93.RD

Award Numbers: Various

Award Periods: Various

### **Summary of Prior Audit Finding**

Condition:

The Clinic does not have an internal control in place over the review and approval of subrecipient invoices to ensure that the payment to the subrecipient is consistent with the terms and conditions of the subaward agreement.

Recommendation:

The Clinic should review its policies and procedures and internal controls over subrecipient cash management to ensure that subrecipients are paid on a cash reimbursement basis.

### **Status**

Completed. Management developed corrective actions following completion of the 2020 single audit in March of 2022. Those corrective actions include new controls and enhancements to existing controls and have been implemented.

### **Contact Person**

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

## **Finding 2021–005**

### **Federal Program Information**

Federal Agencies: United States Department of Education

Federal Cluster: Student Financial Assistance Cluster – Federal Direct Student Loans

Assistance Listing Nos.: 84.268

Award Periods: July 1, 2020 through June 30, 2021, and July 1, 2021 through June 30, 2022

### **Summary of Prior Audit Finding**

Condition:

The Mayo Clinic College of Medicine and Science (MCCMS) did not document the components of its quality assurance system for the Federal Direct Loan program for the year ended December 31, 2021, in a single location. In addition, MCCMS did not retain documentation of its periodic monitoring and evaluation of its direct loan quality assurance system, including results of the assessments and whether any updates or changes were required.

Recommendation:

MCCMS should retain documentation of its periodic monitoring and evaluation of the direct loan

quality assurance system.

**Status**

Completed. MCCM has met the requirements and has taken the following steps during our annual review of policy and procedures:

1. Maintained a single Annual Direct Loan Quality Assurance program document outlining:
  - a. Policies and procedures reviewed
  - b. Outcome of review including changes made
  - c. Name of individual conducting the review
  - d. Date the review occurred
2. Archived a copy of the policy and procedures in our financial aid electronic folder each academic year.
3. Maintained documentation of new federal guidelines or system updates along with confirmation that necessary changes were made according to federal or system requirements.

**Contact Person**

Anne Dahlen, Director of Student Financial Aid/Registrar  
Maribeth Foerster, Program Manager Student Financial Aid

**Finding 2021–009**

**Federal Program Information**

Federal Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)  
Assistance Listing No.: 93.498, COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution  
Award Numbers: Various  
Award Period: January 1, 2021 through December 31, 2021

**Summary of Prior Audit Finding**

Condition:

Management did not retain supporting documentation over its approval of expenses reported to HRSA in the HHS portal. While management had a robust process to identify and review expenses for allowability under the PRF program, sufficient supporting documentation was not retained to support the process.

Recommendation:

Management should reassess its internal controls over the review and approval of allowability of expenditures.

**Status**

Completed. This award has ended, and no further expenditures are expected.

**Contact Person**

Connie Petch, Division Chair Accounting



## **Corrective Action Plan**

### **Finding 2023-001**

#### **Federal Program Information**

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Assistance Listing No.: 84.268, Federal Direct Student Loans (Direct Loans)

Award Periods: July 1, 2022 through June 30, 2023; July 1, 2023 through June 30, 2024

#### **Corrective Action Planned**

Annually, tests of access to Business Objects and properly authorized changes made to the logic within Business Objects specific to the disbursement report used by management will be conducted. Testing will be performed initially by Mayo Clinic's internal audit team and in subsequent years by the Financial Aid Director and Director of Data Analytics.

#### **Persons Responsible for Corrective Action**

Anne Dahlen, Director of Student Financial Aid

Aaron Pendl, Director of Data Analytics

#### **Target Completion Date**

November 30, 2024



## **Corrective Action Plan**

### **Finding 2023-002**

#### **Federal Program Information**

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense

Pass-Through Entities: Georgia Institute of Technology, Massachusetts General Hospital, NYU Grossman School of Medicine, University of Chicago, University of Michigan, and Washington University

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 93.233, 93.273, 93.279, 93.310, 93.350, 93.393, 93.395, 93.396, 93.397, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.865, and 93.866

Award Numbers: Various

Award Periods: Various

#### **Corrective Action Planned**

Management implemented revisions to the monthly/quarterly review packet in January 2024 to ensure review of internal service charges and retention of review documentation. Management's expectations have been communicated to those responsible for the control process regarding timely reviews and retention of documentation.

#### **Persons Responsible for Corrective Action**

Susan Norby, Division Chair - Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair - Financial and Accounting Services, Research Finance

#### **Target Completion Date**

January 31, 2024





## **Corrective Action Plan**

### **Finding 2023-003**

#### **Federal Program Information**

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.RDC, 12.300, 93.393, 93.396, 93.847, 93.853, 93.859

Award Numbers: Various

Award Periods: Various

#### **Corrective Action Planned**

Monthly/quarterly reviews, including completion of subaward monitoring checklists, resumed in January 2024. Management's expectations have been communicated to those responsible for the control process regarding timely checklist completion and retention of documentation.

#### **Persons Responsible for Corrective Action**

Susan Norby, Division Chair - Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair - Financial and Accounting Services, Research Finance

#### **Target Completion Date**

January 31, 2024



## **Corrective Action Plan**

### **Finding 2023-004**

#### **Federal Program Information**

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense

Pass-Through Entities: Boston University, Georgia Institute of Technology, Massachusetts General Hospital, NYU Grossman School of Medicine, Stanford University, The University of Texas, University of Buffalo, University of Chicago, and Washington University

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 93.233, 93.273, 93.279, 93.310, 93.350, 93.393, 93.395, 93.396, 93.397, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, and 93.866

Award Numbers: Various

Award Periods: Various

#### **Corrective Action Planned**

Management has made improvements to the salary cap application to ensure salaries are being correctly charged. The salary cap application is working effectively as of January 1, 2024.

#### **Persons Responsible for Corrective Action**

Susan Norby, Division Chair - Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair - Financial and Accounting Services, Research Finance

#### **Target Completion Date**

January 31, 2024



## **Corrective Action Plan**

### **Finding 2023-005**

#### **Federal Program Information**

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense

Federal Cluster: Research and Development (R&D)

Pass-Through Entity: The University of Texas Health (93.853, NS119834)

Assistance Listing Nos.: 12.420, 93.310, 93.353, 93.393, and 93.853

Award Numbers: W81XWH-15-1-0292 (12.420), OD23121 (93.310), CA246568 (93.353), CA259201 (93.393), NS119834 (93.853), NS122096 (93.853)

Award Periods: Various

#### **Corrective Action Planned**

Management conducted an education and training session for procurement teams in June 2024 to reinforce procurement requirements and documentation standards. Management will implement an independent sanction and debarment check for suppliers as part of existing quarterly audits over Supplier AP vendor master tables and related changes to those tables.

#### **Persons Responsible for Corrective Action**

Daniel Schmitz, Division Chair - Supply Chain Management

Scott Hammer, Director - Supply Chain Management

#### **Target Completion Date**

June 30, 2024